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Summary 
N-methyl-D-aspartate receptors (NMDARs) are voltage- and ligand-gated ion channels and 
key glutamate receptors in the brain. NMDARs play an important role in neuronal 
development, plasticity and excitotoxicity and are implicated in several neurological disorders 
as in Parkinson’s and Alzheimer’s disease, depression or schizophrenia. The blockade of 
NMDAR activity by NMDAR antagonists MK801, memantine and ifenprodil has been used 
to elucidate neuronal NMDAR function. Memantine is currently applied in treatment of 
advanced Alzheimer's dementia. Interestingly, NMDARs were reported to be expressed on 
human T cells and murine thymocytes and their presumable inhibition by NMDAR 
antagonists was shown to influence several cellular responses. The major goals of this study 
were to investigate NMDAR expression in murine CD4+ T helper (Th) and B cells and how 
NMDAR antagonists would modify their function. The expression of NMDAR subunits at 
mRNA level was detected in thymocytes, resting and activated Th cells as well as B cells. 
However, several methodical approaches to detect functional NMDARs at protein level 
remained inconclusive. Analysis of NMDAR knockout mice showed that the reported and by 
us assumed expression of NMDARs in murine thymocytes and T cells is questionable as the 
used and described NMDAR antibodies turned out to be unsuitable for NMDAR detection in 
lymphocytes. Moreover, thymocytes from NMDAR knockout and wildtype mice were 
inhibited to the same degree by NMDAR antagonists, strongly suggesting a cross-reactivity of 
NMDAR antagonists with other ion channels. Within our collaborative project, these were 
identified to be Kv1.3 and KCa3.1 potassium channels. NMDAR antagonists significantly 
reduced Th cell proliferation in a drug concentration- and TCR stimulus-dependent manner. 
This correlated with a reduced activation of PLCγ1, Erk1/2, Akt-mTOR-S6 and NFATc1 and 
thus important TCR-induced signalling pathways. B cells showed comparable responses to 
NMDAR antagonists. BCR-induced and also LPS/TLR4-induced proliferation and activation 
of Erk1/2, Akt-S6 and NFATc1 were strongly attenuated in the drugs’ presence. In addition, 
IgM and IgG secretion of LPS-activated B cells was abolished. However, the frequency of 
BCR/CD40-stimulated B cells producing the immunosuppressive cytokine IL-10 was 
significantly enhanced by ifenprodil. Hence, NMDAR antagonists may be of high therapeutic 
potential to suppress/modulate T- and B-cell responses in autoimmune diseases or 
pathological systemic inflammation. Furthermore, the additional (possibly beneficial) side 
effects of NMDAR antagonists, like memantine, on T and B cells should be considered when 
these drugs are used in treatments of neuronal diseases.  
  
  
  Zusammenfassung 
 
 
7 
 
Zusammenfassung 
N-Methyl-D-Aspartat-Rezeptoren (NMDARs) sind spannungs- und liganden-gesteuerte 
Ionenkanäle und gehören zu den wichtigsten Glutamatrezeptoren im Gehirn. NMDARs 
spielen eine entscheidende Rolle in der neuronalen Entwicklung und Ausbildung neuronaler 
Plastizität und sind maßgeblich an neuronaler Exzitotoxizität beteiligt. Eine Fehlfunktion der 
Rezeptoren ist mit verschiedenen neuronalen Erkrankungen assoziiert, u.a. Schlaganfall, 
Parkinson, Alzheimer, Depression und Schizophrenie. Die Blockade der NMDAR-Aktivität 
durch Antagonisten, wie MK801, Memantin und Ifenprodil, hat zum Verständnis der 
NMDAR-Funktionen wesentlich beigetragen. Memantin wird derzeit als zugelassenes 
Medikament klinisch eingesetzt, um die Symptomatik fortgeschrittener Alzheimer Demenz 
einzudämmen. Interessanterweise wurde die Expression von NMDARs auch für humane T-
Zellen und murine Thymozyten beschrieben und ihre angenommene Hemmung durch 
NMDAR-Antagonisten beeinflusste die Proliferation, Differenzierung und Apoptose der 
Zellen. Ein Ziel der vorliegenden Forschungsarbeit war der Nachweis funktioneller NMDARs 
in murinen CD4+ T-Helfer Zellen (Th) sowie B-Zellen. Zudem sollten die möglichen 
Auswirkungen von NMDAR-Antagonisten auf die Funktionen muriner Lymphozyten 
untersucht werden. Die Expression von NMDAR-Untereinheiten auf RNA-Ebene wurde in 
Thymozyten, ruhenden und aktivierten Th-Zellen sowie B-Zellen mittels RT-PCR 
nachgewiesen. Allerdings konnte trotz verschiedener experimenteller Methodik die 
Expression von NMDARs auf Proteinebene nicht überzeugend bestätigt werden. Analysen 
von Thymoyzten aus NMDAR-defizienten Mäusen zeigten, dass die zuvor beschriebene und 
von uns angenommene Expression funktioneller NMDARs in murinen Thymozyten und 
peripheren T-Zellen zumindest sehr fraglich ist, da nachgewiesen wurde, dass mehrere, hier 
und zuvor in der Literatur eingesetzte, NMDAR-Antikörper unspezifisch agieren und für den 
Nachweis von NMDARs in Lymphozyten ungeeignet sind. Zudem wurde die Proliferation 
von Thymozyten aus NMDAR-defizienten und Wildtyp-Mäusen durch NMDAR-
Antagonisten im gleichen Ausmaß gehemmt. Dies zeigt, dass NMDAR-Antagonisten 
vornehmlich über die Kreuzinhibition anderer Ionenkanäle agieren. In unserem 
Kooperationsprojekt wurden Kv1.3 und KCa3.1 Kalium-Kanäle als „targets“ von NMDAR-
Antagonisten aufgezeigt. NMDAR-Antagonisten blockierten die Th-Zellaktivierung und 
Expansion in Abhängigkeit ihrer Konzentration und der Stärke des TCR-Stimulus, wobei 
CD28-Kostimulation diese inhibitorische Wirkung weitgehend aufhob. Auf mechanistischer 
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Ebene schwächten NMDAR-Antagonisten die Aktivierung von PCLγ1, Erk1/2, Akt-mTOR-
S6 und des Transkriptionsfaktors NFATc1 und somit die Aktivierung zentraler TCR-
induzierter Signalkaskaden. Vergleichbare Ergebnisse wurden für B-Zellen erzielt. 
Interessanterweise wurde sowohl die BCR- als auch LPS/TLR4-induzierte Proliferation der 
B-Zellen durch die Antagonisten stark gehemmt, was mit einer verminderten Aktivierung von 
Erk1/2, Akt-S6 und NFATc1 in den B-Zellen korrelierte. Zudem verringerten die 
Antagonisten die IgM- und IgG-Produktion LPS-stimulierter B-Zellen. Hingegen wurde die 
Differenzierung BCR/CD40-stimulierter B-Zellen, die das immunsuppressive Zytokin IL-10 
produzieren, durch Ifenprodil signifikant erhöht. Insgesamt implizieren meine gewonnenen 
Daten, dass NMDARs in (murinen) Lymphozyten keine bzw. nur eine untergeordnete Rolle 
spielen. NMDAR-Antagonisten könnten durch Kreuzinhibition von Kv1.3 und KCa3.1 
Kanälen ein profundes therapeutisches Potential auf pathologische adaptive und angeborene 
Immunantworten haben. Durch die Suppression bzw. Modulation der T- und B-
Zellfunktionen könnten sie z.B. die Immunantwort bei Autoimmunerkrankungen und 
systemischen Entzündungsreaktionen günstig beeinflussen. Andererseits sollten die 
beschriebenen (eventuell  positiven) Auswirkungen auf T- und B-Zellen im Nebenwirkungs-
profil von NMDAR-Antagonisten, wie Memantin, beachtet werden, wenn sie als Medikament 
bei der Behandlung neurologischer Erkrankungen eingesetzt werden. 
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1. Introduction 
1.1 The adaptive immune system 
To protect from infectious agents, vertebrates have developed a complex biological system of 
self-defence mechanisms, commonly called the immune system. The immune system is 
divided into innate (inborn) and adaptive (acquired) immunity. Innate immunity is non-
specific and has no immunologic memory. Adaptive immunity recognizes and memorizes 
pathogens through antigen-specific mechanisms and provides long-term protection to the host 
against re-infection by the same pathogens.  
Adaptive immune responses are mediated by B and T lymphocytes, which provide humoral 
and cellular responses, respectively. B cells produce antibodies (Abs), which are released into 
the blood stream and other body fluids. The Abs bind to viruses, microorganisms or toxins 
and can neutralize them leading to their elimination. Cellular immune responses are mediated 
by CD4+ or CD8+ T cells. Cytotoxic CD8+ T cells eradicate virus-infected host cells and 
take part in the elimination of tumor cells. CD4+ T helper (Th) cells regulate immune 
responses by secreting cytokines and providing co-stimulatory signals for the activation of 
macrophages, CD8+ T cells, B cells, and other immune cells (Murphy, 2012). 
My thesis dealt with the analysis of signalling events in murine T and B cells with regard to 
the role of NMDARs (N-methyl-D-aspartate receptors), ionotropic glutamate receptors that 
are well characterized in neuronal cells and had been reported to be also functional in human 
T cells. Thus, in the following chapters short overviews on the development and activation of 
T and B cells will be given followed by an overview on NMDARs, their antagonists and 
proposed role in lymphocytes.  
1.2 Development and function of T cells 
Lymphocytes are responsible for the incredible specificity of adaptive immune responses to 
eliminate foreign antigens and help in activating other immune cells. They originate from 
multi-potent haematopoietic stem cells in the bone marrow. Some of the lymphoid progenitor 
cells leave the bone marrow and migrate via the blood stream into the thymus. In the thymus, 
the early progenitor cells receive signals to mature via several concrete differentiation steps 
into functional T cells, which leave the thymus to seed peripheral lymphoid organs like spleen 
and lymph nodes.  
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The maturation stages of thymocytes are distinguishable by the expression of stage-specific 
surface molecules. The early thymocyte progenitors lack CD4 or CD8 surface markers and 
therefore are called double negative (DN) thymocytes. DN cells arise in the cortical region of 
the thymus and in the mouse system are sub-divided into four stages, based on the expression 
of CD25 and CD44 molecules (Figure 1a). 
 
 
Figure 1. Schematic representation of T- and B-cell development. Common lymphoid progenitors 
(CLP) in the bone marrow give rise to both T- and B-cell lineages. a) T-cell development in the 
thymus. T-cell progenitors differentiate from double negative (DN) to double positive (DP) cells. At 
the DN2/DN3 stage, TCRβ-chain rearrangement takes place leading to the expression of a pre-TCR. 
Rearrangement of the TCRα-chain leads to the expression of mature α/β TCRs on DP thymocytes. DP 
cells are surveyed for the ligand binding affinity of their TCRs and undergo either positive or negative 
selection. DP cells that are positively selected will commit to either the CD4 or CD8 lineage. 
Negatively selected DPs die by apoptosis, thus avoiding the generation of autoreactive T cells. Mature 
single positive (SP) CD4+ and CD8+ T cells leave the thymus and migrate into secondary lymphoid 
organs. b) B cells develop from CLP in the bone marrow. Pro-B cells employ VDJµ rearrangement to 
generate a pre-BCR and differentiate into large pre-B cells. Signalling through the pre-BCR induces 
proliferation of large pre-B cells and their maturation into small pre-B cells. Rearrangement of κ- or λ-
chains and their pairing with the IgM heavy chain generates a functional BCR on immature B cells. 
Are these positively selected, they migrate into the spleen to express IgD and finish maturation. 
Immature B cells that are not positively selected will rearrange further BCRs by receptor editing to 
clear positive selection or are negatively selected and die by apoptosis. Figure adapted from (Engel 
and Murre, 2001). 
 
Thymus
a
b
Bone marrow
Periphery
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DN1 cells are CD44+CD25- and differentiate into CD44+CD25+ DN2 cells. Chemokines 
induce the migration of DN1/2 cells from the thymic cortex into the sub-cortex leading to the 
maturation of CD44-CD25+ DN3 cells. At the DN3 stage, cells start the rearrangement of the 
T cell receptor (TCR) β-chain, which combines with a surrogate pre-TCRα-chain (pTα) to 
form the pre-TCR, together with CD3γ, CD3δ, CD3ε and ζ chains of the CD3 complex. 
Failure to express a pre-TCR leads to the blockade of thymocyte development and DN3 cell 
cell death by apoptosis, a process known as β-selection (Germain, 2002; Swat et al., 1991). 
DN3 cells that cleared β-selection undergo proliferation via signals transduced by the pre-
TCR, loose CD25 surface expression and mature into CD25-CD44- DN4 stage cells. Pre-
TCR-induced survival and proliferation initiates arrest of further β-chain rearrangements 
(allelic exclusion) ensuring an individual β-chain on each cell. In DN4 cells, the expression of 
CD8 and CD4 surface markers is induced leading to the maturation of double positive (DP) 
thymocytes. At this point, extensive TCRα-chain rearrangements take place resulting in the 
formation of a heterodimeric 'mature' TCR bearing α- and β-chains (Figure 1a). DP cells 
undergo the second developmental checkpoint by testing the functionality of the TCR (αβ-
selection) for MHC/self-peptide recognition and self-tolerance. The selection processes of DP 
cells are highly complex. In a simplified model, the strength and duration of TCR and co-
receptor signals upon interaction of TCRs with MHCI- or MHCII-self-peptides presented on 
thymic epithelial cells and dendritic cells (DCs) determine whether DP cells die by so-called 
'death of neglect' or by negative selection or whether they are positively selected and survive 
to further mature into single positive (SP) CD4+ Th or CD8+ cytotoxic T cells (lineage 
commitment). Importantly, these processes generate a self-tolerant and functional T-cell pool 
with an immense TCR repertoire that is able to protect the organism from a plethora of 
foreign antigens (Klein et al., 2014; Starr et al., 2003).  
Upon encounter of their cognate antigen displayed on MHCI/II molecules of antigen 
presenting cells (APC), naive peripheral T cells get activated, undergo clonal expansion and 
differentiate into discrete T effector cell subsets. Th cell subsets are marked by their specific 
cytokine profiles or in case of cytotoxic CD8+ T cells by the production of granzymes and 
perforins. Th cells also interact with B cells to foster their activation and differentiation and 
migrate into inflammatory sites of infection to activate other cell types, thus helping in 
clearing the infection. Some of the antigen-experienced effector T cells differentiate into 
antigen-specific memory T cells (Chaplin, 2006; Murphy, 2012) . 
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Depending on the TCR stimulus, cytokine environment and the induction of specific 'master' 
transcription factors, activated Th cells differentiate into various Th cell subsets such as Th1, 
Th2, Th17, and regulatory T cells (Tregs), which show a specific cytokine secretion profile 
and specific effector functions. For instance, Th1 cells secrete IL-2 (interleukin 2) and IFN-γ 
(interferon γ) and activate the killing mechanisms of macrophages to destruct ingested 
intracellular pathogens. Th1 cells also help in clearing the infection by activating and 
recruiting cytotoxic CD8+ T cells and NK cells into the inflamed tissues. Th2 cells secrete IL-
4, IL-5, IL-6, IL-9, IL-10, and IL-13 cytokines and are involved in the regulation B-cell 
proliferation, Ig (immunoglobulin) class switching and their differentiation into Ab secreting 
plasma cells. Th17 cells secrete IL-17 cytokines and deliver inflammatory responses in anti-
microbial and fungal defences. Tregs, induced in the periphery (pTregs) or matured in the 
thymus (tTregs) secrete IL-10 and TGF-β (transforming growth factor β) and act as important 
regulators of peripheral self-tolerance, chronic inflammation and autoimmune disorders (Zhu 
and Paul, 2008).  
Cytotoxic CD8+ T cells (CTL) are involved in the killing of virus infected cells and 
eradication of intracellular pathogens. By production of several soluble factors such as 
perforin, granzyme, granulysin, IFN-γ, and TNF-α (tumor necrosis factor-α), they are also 
crucial for the elimination of tumor cells. TNF-α also co-operates with IFN-γ in the activation 
of macrophages.  
1.2.1 T-cell signalling 
Ligtion of the TCR by antigen presented by DCs, macrophages or B cells results in the 
activation of a TCR-induced complex signalling network including second messengers, 
kinases, phosphatases, and adaptor molecules. These regulate the activation of central 
signalling pathways, which lead to the activation of the transcription factors NFAT (nuclear 
factor of activated T cells), NFκB (nuclear factor kappa light chain enhancer of activated B 
cells) and AP1 (activator protein 1), which, among others, control IL-2 transcription and T-
cell activation.   
The positively charged TCRαβ heterodimer associates with the negatively charged CD3 
complex, which transmits signal transduction. The CD3 chains harbour in their cytoplasmic 
tails immunoreceptor tyrosine-based activation motifs (ITAMs) which consist of two 
conserved YXXL or YXXI motifs separated from each other by 6-8 amino acids. In total, the 
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TCR/CD3 complex contains 10 ITAMs, formed from three ITAMs in each ζ-chain and one 
ITAM in each CD3ε-, γ- and δ-chain (Chakraborty and Weiss, 2014; Smith-Garvin et al., 
2009). TCR engagement induces the activation of the major Src kinase Lck (lymphocyte-
specific protein tyrosine kinase) which phosphorylates the ζ-chain ITAMs (Isakov et al., 
1995) leading to the recruitment of ZAP-70 (zeta-chain-associated protein kinase of 70 kD) 
and its phosphorylation and activation by Lck (Acuto et al., 2008; Yan et al., 2013) (Figure 
2). Active ZAP-70 phosphorylates the adaptor proteins LAT (linker for activation of T cells) 
and SLP-76 (SH2-domain containing leukocyte protein of 76 kD) recruited to pLAT (Paz et 
al., 2001).  
                
Figure 2. Schematic overview of TCR-induced signalling events. TCR-induced proximal 
signalling includes phosphorylation of the ITAMs of the TCR/CD3 complex by activated 
Lck, Zap70 activation by Lck and formation of a signalosome complex at phosphorylated 
LAT. More distal signalling events include formation of IP3 and DAG by activated PLCγ1, 
which lead to the activation of the Ca2+/calcineurin/NFAT, Ras/Raf/Mek/Erk and PKC/NFκB 
cascades, respectively. TCR as well as CD28 ligation also induces activation of the lipid 
kinase PI3-K leading to the activation of Akt, mTOR and phosphorylation of ribosomal 
protein S6. Activated NFAT, AP1, and NFκB transcription factors initiate IL-2 cytokine 
transcription, which supports T-cell activation and proliferation. Figure adapted from (Love 
and Hayes, 2010; Nakayama and Yamashita, 2010).   
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Phosphorylated LAT recruits further signalling molecules to the plasma membrane including  
Gads (Grb2-related adapter downstream of Shc), PLCγ1 (phospholipase C gamma 1), Grb2 
(growth factor receptor-bound protein 2) and Sos (son of sevenless), Itk (inducible T cell 
kinase), lipid kinase PI3-K (phosphoinositide 3-kinase), Vav (named after the sixth letter of 
the Hebrew alphabet) and the adaptor proteins Nck (non-catalytic region of tyrosine kinase 
adapter protein) and ADAP (adhesion and degranulation-promoting adapter protein) 
(Balagopalan et al., 2010; Fuller et al., 2011; Kliche et al., 2006; Liu et al., 1999; Sylvester et 
al., 2010). The assembled multi-protein LAT complex forms the Ca2+-signalosome and 
signalling podium for activation of the MAPK (mitogen-activated protein kinase) Erk1/2 
(extracelluar signal-regulated kinase 1 and 2) and PKC (protein kinase C). Activated PLCγ1 
hydrolyzes the breakdown of the membrane lipid PIP2 (phosphatidylinositol 4, 5-
biphosphate) into the second messengers IP3 (inositol 1, 4, 5-triphosphate) and DAG 
(diacylglycerol). IP3 activates the Ca2+-dependent signalling pathway and DAG initiates 
activation of PKC and Erk1/2 (Smith-Garvin et al., 2009). These major signalling events 
induce the activation of NFAT, NFκB and AP-1, respectively (Figure 2). 
1.2.2 The Ca2+ - calcineurin - NFAT pathway 
In the cytoplasm, NFAT factors exist in the inactive phosphorylated form (Sharma et al., 
2011). Their canonical activation requires elevated intracellular Ca2+-levels and de-
phosphorylation by the phosphatase calcineurin. IP3, generated by active PLCγ1, binds to IP3 
receptors located in the endoplasmic reticulum (ER) membrane, leading to the release of Ca2+ 
from intracellular stores into the cytoplasm. Reduced Ca2+-levels in the ER are sensed by ER 
high affinity calcium sensor proteins STIM1/2 (stromal interaction molecule 1/2) which 
mediate opening of the plasma membrane CRAC (calcium release activated channel) 
channels (Gwack et al., 2007; Hogan and Rao, 2015; Weiss, 2009). Influx of Ca2+ through 
CRAC channels induces the activation of Ca2+/CaM (calmodulin)-dependent enzymes like 
calcineurin. Calcineurin activates NFAT factors through dephosphorylation of at least 13 
phosphoserines in the regulatory region of NFAT, thereby promoting its translocation into the 
nucleus (Figure 2) (Robert et al., 2011). In my thesis, I focussed on the analysis of NFAT 
family member NFATc1 (NFAT2), which is transcriptionally induced and activated in naive 
Th cells upon TCR triggering (Chuvpilo et al., 2002). NFATc1 plays an important role in 
thymocyte development (Patra et al., 2013; Patra et al., 2006), the regulation of cytokine and 
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cytokine receptor expression, T-cell apoptosis, proliferation and Th cell differentiation (Rao 
et al., 1997; Rudolf et al., 2014; Serfling et al., 2007; Serfling et al., 2006). 
1.2.3 The Ras-Erk-AP-1 pathway 
The AP-1 transcription factor is a dimeric protein complex of Jun and Fos (FBJ murine 
osteosarcoma viral oncogene homolog) family transcription factors and its formation is 
dependent on Jnk (c-jun N terminal kinase) and Erk1/2 signalling. DAG, generated from PIP2 
by active PLCγ1, activates PKC and the GTP exchange factor RasGRP (rat sarcoma guanyl-
releasing protein) which is involved in the activation of Ras. Ras activates the MAPKinase 
cascade by binding to the serine/threonine kinase c-Raf (rapidly accelerated fibrosarcoma) 
through its Ras binding domain. Activated c-Raf dimerizes and activates MEK (mitogen 
activated protein/Erk kinase), the upstream kinase of Erk1/2. Erk1/2 regulates gene 
transcription either directly by phosphorylating and stabilizing the transcription factors cFos 
and cMyc or indirectly by phosphorylating Rsk (ribosomal S6 kinase) and Elk (ETS-like 
transcription factor). AP-1 in concert with NFAT functions as a transcriptional activator and 
initiates the expression of CD69, which is known as an early marker of T-cell transcriptional 
activation (Smith-Garvin et al., 2009). 
1.2.4 Activation of the PI3-K-Akt-mTOR pathway 
Besides triggering of the TCR (signal 1), T-cell activation requires additional signals provided 
by co-stimulatory receptors like CD28 (signal 2). CD28 binds to its ligands CD80 (B7-1) and 
CD86 (B7-2) expressed on the surface of activated APCs and induces signals that synergize 
with TCR-induced signalling events supporting T-cell activation, survival, and differentiation 
(Rudd et al., 2009). Both, TCR and CD28 ligation induce the activation of lipid kinase PI3-K, 
which converts PIP2 into PIP3. Membrane anchored PIP3 serves a docking site for PH 
(pleckstrin homology)-domain containing proteins like PDK1/2 (phosphoinositide-dependent 
protein kinase 1/2) and protein kinase B (PKB), also known as Akt (Figure 2). Akt is 
phosphorylated by PDK1 and mTORC2 (mammalian target of rapamycin complex 2) and is a 
central regulator of cell growth and survival. Akt signalling leads to the activation of mTOR 
and p70S6Kinase, which phosphorylates ribosomal protein S6, thereby fostering protein 
synthesis. Phosphorylation of GSK3β (glycogen synthetase kinase 3 β) by Akt inactivates 
GSK3β (Cross et al., 1995), which is one of the constitutively active NFAT kinases and a 
negative regulator of NFAT activation (Diehn et al., 2002). Once T cells are activated, their 
functional responses are further regulated through different cytokine signals (signal 3).  
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1.3 Development and function of B cells 
B lymphocytes provide antigen-specific and long-term defence against different pathogens 
through the production of high affinity Abs of different isotypes. However, B cells can also 
induce or contribute to disease, for instance in autoimmune diseases by the production of 
autoantibodies as in MS (multiple sclerosis) or lupus erythematosus (Yanaba et al., 2008). 
Autoantibodies against neurotransmitter receptors or voltage-gated ion channels in the brain 
influence the opening behaviour of neuronal ligand- and voltage-gated ion channels (Kleopa, 
2011) and lead to synaptic dysfunction. Such autoantibodies were observed in Rassmussen 
encephalitis (Rogers et al., 1994), Lambert Eaton myasthenic syndrome (Lennon et al., 1995) 
or anti-NMDAR encephalitis (Finke et al., 2013; Ramanathan et al., 2014; Sansing et al., 
2007).  
B cells differentiate from CLPs in the bone marrow. Pro-B cells form the earliest progenitors 
committed to the B-cell lineage (Figure 1b). They express two B-cell lineage specific 
transcription factors, E-protein E2A and EBF (early B-cell factor), which are required for 
formation of the pre-BCR (pre-B cell receptor) in pro-B cells (Melchers, 2005). With the help 
of RAG1/2 (recombinase activationg gene), E2A and EBF initiate gene rearrangements at the 
Ig heavy chain locus, usually in the µ region. Once a heavy µ chain is successfully formed, it 
is expressed on the surface with two surrogate chains called λ and VpreB and the two 
invariant chains Igα and Igβ forming the pre-BCR (ten Boekel et al., 1998). Expression of the 
heavy chain stops rearrangements in the heavy chain locus of the pro-B cell to prevent a B 
cell producing two receptors of different antigen specificities (allelic exclusion). Pro-B cells 
that fail to produce a functional heavy chain are eliminated by apoptosis. The pre-BCR 
complex provides signals for the rearrangement of the Ig light chain genes and allows a pro-B 
cell to proceed to the next stage of development. Once formed, pre-B cells initiate gene 
recombination in the Igκ or Igλ light chain locus. Successfully rearranged light chains are 
paired with the µ chains to form complete surface IgM molecules (van Zelm et al., 2007). At 
this stage, IgM in association with Igα and Igβ forms a functional BCR complex and B cells 
are called immature B cells (Figure 1b). The BCR is tested for autoreactivity and the signals 
generated from the BCR complex upon engagement with specific antigen dictate the fate of 
immature B cells. Cells with BCRs that strongly recognise autoantigens are eliminated by 
apoptosis, inactivated by immunological unresponsiveness (anergy) or immunological 
ignorance. In addition to these selection processes, autoreactive immature B cells can be 
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rescued by further gene rearrangements in their light chains to produce a new BCR that is not 
self-reactive (receptor editing). Immature B cells that are not strongly self-reactive will 
eventually transform into mature B cells and migrate into the spleen where they undergo final 
maturation (Figure 1b) (Murphy, 2012). Mature B cells are characterised by the expression of 
IgM and IgD molecules and receive survival signals from BCR engagement with antigen and 
BAFF (B cell activating factor) receptors (Kraus et al., 2004).  
Activated naive B cells differentiate into several B-cell subsets that are involved in protective 
humoral immune responses. A subpopulation of B cells, called B10 cells, displays 
immunomodulatory functions by producing the immunosuppressive cytokine IL-10. B10 cells 
require for their formation BCR engagement and activation via the CD40 receptor or LPS 
(lipopolysaccharide) stimulation (Blair et al., 2009; Poe et al., 2011; Yanaba et al., 2009). 
They play a crucial role in preventing inflammatory and autoimmune pathologies and a lack 
of or inhibition of B10 cells has been associated with exacerbated experimental autoimmune 
encephalitis (EAE) (Fillatreau et al., 2002; Matsushita et al., 2008), collagen-induced arthritis 
(Mauri et al., 2003) or colitis in mice (Baba et al., 2015; Bouaziz et al., 2008; Candando et al., 
2014). 
1.3.1 B-cell signalling 
The BCR complex comprises a transmembrane Ig and Igα and Igβ molecules for signal 
propagation (Burkhardt et al., 1991). BCR ligation leads to the phosphorylation of the ITAMs 
in the cytoplasmic tails of Igα and Igβ by the Src kinases Lyn (Lck/Yes novel tyrosine 
kinase) and Fyn (feline-yes related protein) (Kurosaki, 1999). The phosphorylated ITAMs 
recruit Syk (SH2 domain containing tyrosine kinase) and activated Syk phosphorylates the 
adaptor protein SLP-65 (SH2-domain containing leukocyte protein of 65 kD, also known as 
BLNK). SLP-65 forms a signalosome by recruiting several kinases and adaptor proteins such 
as Btk (Bruton’s tyrosine kinase), PLCγ2 and Grb2 (Figure 3) (Ackermann et al., 2011; Rolli 
et al., 2002). PLCγ2 is activated by Btk and then hydrolyzes PIP2 into the second messengers 
IP3 and DAG. These lead to Ca2+-mobilization, activation of PKC, Ras/Raf/Mek/Erk1/2, 
NFAT factors and NFκB, as described above for T cells (Wienands and Engels, 2001).  
The BCR functionally associates with the B cell co-receptor CD19 that upon ligation recruits 
PI3-K, Vav and Lyn to the phosphorylated tyrosine residues in its cytoplasmic tail (Wang et 
al., 2002). PI3-K, induced by CD19 or the BCR, initiates Akt-mTOR-S6 signalling which is 
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important for B-cell development, activation, growth and survival (Okkenhaug et al., 2014; 
Pierau et al., 2012; Wienands and Engels, 2001).  
CD40 is another important receptor on B cells. Its ligation by CD40L, expressed on activated 
Th cells, induces cell cycle and cell survival promoting genes; it also regulates Ig class 
switching and somatic hypermutation in B cells. CD40 signalling includes activation of 
Erk1/2, Jnk and p38 kinases that are involved in the activation of the transcription factors Elk-
1 (ETS-like transcription factor), AP-1 and ATF1 (activating transcription factor 1). CD40 
triggering also induces activation of PI3-K, NFκB, and Jak-Stat (janus activated kinase-signal 
transducer activator of transcription) proteins (Harnett, 2004). As mentioned before, BCR 
plus CD40 signals are critical to induce B10 cell generation. 
       
Figure 3. Schematic overview of B-cell signalling. The BCR complex consits of IgM and Igα/Igβ 
signal transducing molecules. Upon BCR ligation, the Src kinase Lyn is activated and phosphorylates 
the ITAMs of the BCR complex to initiate proximal signalling events. Syk recruited to pITAMs 
becomes activated and phosphorylates SLP65 (BLNK), which then recruits Btk, Grb2, Vav and 
PLCγ2. Activated PLCγ2 hydrolyzes PIP2 into DAG and IP3 second messengers. DAG is involved in 
the activation of PKC-NFκB and Ras-Raf-Mek-Erk1/2 cascades. IP3 mediates CRAC channel 
opening and NFAT activation. PI3-K is activated by BCR and CD19 ligation and initiates Akt-mTOR-
S6 signalling. Activated transcription factors like NFAT and NFκB initiate changes in gene expression 
important for clonal proliferation and differentiation into plasma or memory B cells. Figure adapted 
from (Baba and Kurosaki, 2011). 
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1.4 TLR signalling 
The innate immune response is the first line of defence to protect the host from invaded 
pathogens. Previously, innate immunity was considered as a system that only works through 
non-specific immune responses by phagocytic cells such as macrophages, neutrophils and 
DCs, which engulf and eliminate the microbial pathogen. Later, it was revealed that the fly 
Drosophila expresses special receptors for recognizing fungal infections, called Toll receptors 
(Akira et al., 2001). A human homolog of Toll was then shown to have the ability to induce 
the expression of inflammatory cytokines and co-stimulatory molecules (Janeway and 
Medzhitov, 2002). Until now, 13 members of Toll-like receptors (TLRs) have been identified 
in mice and 10 in humans, which are involved in the activation of innate immune cells and B 
cells. TLRs recognize PAMPs (pathogen associated molecular patterns) that are highly 
conserved motifs of pathogens. Every TLR has its individual pattern recognition specificity 
(Lee and Kim, 2007), for example TLR1, 2 and 6 recognize several bacterial components 
such as peptidoglycans, lipopeptides and lipoproteins, TLR3 binds double stranded RNA 
produced during viral infection (Alexopoulou et al., 2001) and TLR5 recognizes bacterial 
flagellin (Hayashi et al., 2001). TLR4 recognizes LPS of Gram-negative bacteria (Hoshino et 
al., 1999), which induces polyclonal activation of B cells. 
TLRs recognizing PAMPs signal through adaptor molecules such as MyD88 (myeloid 
differentiation factor 88), TIRAP (TIR domain-containing adapter protein), TRIF (TIR 
domain-containing adapter inducing interferon-β), and TRAM (TRIF related adapter 
molecule).  TLR3 and TLR4 activate MyD88- and TRIF-dependent pathways and induce type 
1 interferon IFN-β. TLR-induced signalling results in the activation of IRAK1/4 (IL-1R 
associated kinase 1/4), TRAF6 (tumor necrosis factor associated receptor 6), Erk1/2, Akt  and 
the  transcription factors NF-κB, AP1, NFAT, and IRFs (interferon regulatory factors) (Kawai 
and Akira, 2006). TLR4 plays a major role in the initiation of inflammation and is a potent 
drug target to prevent severe sepsis, which is the primary cause of death amongst severely ill 
patients (Rauch et al., 2012). 
In the part of my thesis dealing with the influence of NMDAR antagonists on T- and B-cell 
signalling, I used CD3, CD3 plus CD28 Abs and IgM (Fab')2 and CD40 Abs or LPS for the 
polyclonal activation of T and B cells, respectively. Changes in the activation of Lck/Fyn, 
PLCγ1, Erk1/2, Akt-mTOR-S6, GSK3β, and NFATc1 were used as a read-out for the effects 
of NMDAR antagonists on the above described major signalling pathways in T and B cells. 
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These signalling molecules are crucial for B- and T-cell activation, and their inhibition by 
several pharmaceutical drugs, like rapamycin, cyclosporine A or Erk inhibitors, is in medical 
use or clinical trial to suppress pathological lymphocyte responses in various immune 
diseases. 
1.5 Neuronal glutamate receptors  
Glu (glutamate) is the major excitatory neurotransmitter in the CNS (central nervous system). 
GluRs (glutamate receptors) are involved in crucial neuronal functions such as neuronal 
development and synaptic plasticity, thereby providing the molecular basis for learning and 
memory. In pathophysiological conditions, they mediate excitotoxicity and neuronal 
degeneration. GluRs are classified into mGluRs (metabotropic) and iGluRs (ionotropic) 
receptors (Mayer, 2005).  
mGluRs belong to the superfamily of G-protein-coupled receptors. They are composed of an 
extracellular domain binding Glu, a transmembrane region consisting of seven 
transmembrane domains and an intracellular region. The mGluR family encompasses eight 
receptor subtypes, which are classified into three groups (I, II and III) based on the amino acid 
sequence homology, agonist receptor pharmacology and intracellular signal transduction 
(Conn, 2003; Niswender and Conn, 2010). Group I receptors are mGlu1R and mGlu5R, 
Group II receptors comprise mGlu2R and mGlu3R, and Group III receptors contain mGlu4R, 
mGlu6R, mGlu7R, and mGlu8R. Glu binding to Group I receptors activates PLCγ1 leading to 
the activation of Ca2+, Erk1/2, and PKC signalling. Group II and III receptors are negatively 
linked to adenyl cyclase and their activation reduces the levels of intracellular cAMP 
(adenosine 3-5 cyclic monophosphate) (Ferraguti and Shigemoto, 2006). 
iGluRs are ligand-gated ion channels, which form homo- or heteromeric channels with four 
transmembrane domains. The main function of iGluRs is to mediate excitatory synaptic 
transmission in the CNS. They are classified into three groups based on their sensitivity to 
pharmacological agonists and structural properties: AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxasolepropionic acid), KA (kainate) and NMDA (N-methyl-D-aspartate) receptors 
(Wisden and Seeburg, 1993). The AMPA and KA receptors induce synaptic transmission 
through permeability of Na2+ ions in response to Glu binding (Nakanishi, 1992). Within 
iGluRs, NMDA receptors (NMDARs) have distinctive features: a pre-requisite for the 
immediate binding of Glu and the co-agonist glycine/D-serine, a voltage-dependent Mg2+-
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block, and a high permeability for Ca2+, which presents their major role in neuronal 
development, synaptic plasticity, learning, and memory. 
1.6 NMDARs and their antagonists 
NMDARs are heterotetrameric ion channels consisting of the obligatory GluN1 subunit and 
two homodimeric or heterodimeric subunits called GluN2A-D, GluN3 or GluN4 (Figure 4). 
When NMDARs bind Glu or aspartate and the co-agonists glycine or D-serine, they become 
activated and induce a depolarization of the cell membrane potential. Glu and NMDA bind to 
the GluN2 subunit and glycine/D-serine to the GluN1 subunit of NMDARs (Johnson and 
Ascher, 1987). Although glycine levels are more abundant than D-serine levels, several 
studies showed that endogenous D-serine is the major exogenous co-agonist for NMDAR-
mediated neurotoxicity (Shleper et al., 2005). 
 
In addition to binding of Glu and glycine/D-serine, activation of NMDARs requires an initial 
membrane depolarization by AMPA receptors to remove the Mg2+-block of the channel pore, 
before the channel pore can be opened to permeate the influx of Ca2+ and Na+ and the efflux 
of K+ ions (Mayer, 2005; Mayer et al., 1984). The NMDAR opening kinetic depends on the 
subunit composition. Thus, NMDARs serve as co-incidence detectors and can initiate 
particular intracellular signalling events through the induction of intracellular Ca2+-changes at 
small domains below the neuronal plasma membrane (Paoletti and Neyton, 2007). The 
localization and composition of NMDARs in the neuronal membrane are fundamental for the 
initiation of these signalling events (Groc et al., 2006). 
Figure 4. Structure and binding 
sites of NMDARs. The binding sites 
for Glu/NMDA, endogenous co-
agonists glycine or D-serine, and 
antagonists are indicated. The 
competitive antagonist D-APV binds 
to the Glu/NMDA site and the 
uncompetitive antagonists MK801 
and memantine in the open channel 
pore region. The non-competitive 
antagonist ifenprodil binds to the 
polyamine site of the GluN2 subunit. 
Figure modified from (Tomek et al., 
2013). 
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In a pathophysiological role, NMDARs are associated with several neuronal disorders due to 
the induction of excitotoxic cell death as in epilepsy and stroke (Shohami and Biegon, 2014; 
Yuan et al., 2015), neurodegenerative diseases like Parkinson, Huntington (Daggett and Yang, 
2013) and Alzheimer (Malinow, 2012), and psychiatric disorders like schizophrenia (Paoletti 
et al., 2013), and depression (Machado-Vieira et al., 2010). These diseases are connected to 
altered NMDAR activity and signalling after their activation. NMDAR-mediated Ca2+-influx 
induces the activation of Ca2+-regulated  proteins such as CamKII (Ca2+-Calmodulin regulated 
kinase II) and NFAT. NMDAR activity also results in the activation of PKC family members, 
Erk1/2 and PI3-K/Akt signalling and further transcription factors that orchestrate specific 
gene expression programs to regulate neuronal homeostasis, plasticity or cell death (Salter et 
al., 2009).  
Since NMDARs are associated with several neuronal disorders, inhibition or modulation of 
NMDAR activity is of great clinical interest. In vitro blockade of NMDARs by several types 
of antagonists has been useful to understand their pharmacology and molecular function. 
NMDAR antagonists are classified into competitive, non-competitive and uncompetitive 
inhibitors. A competitive antagonist like D-APV competes with the agonist Glu or NMDA by 
binding to the same binding site of the GluN2 subunit of NMDARs (Figure 4). Non-
competitive antagonists can act via binding to the active site or to an allosteric site of the 
receptor that is distinct from the active site or agonist binding site. Ifenprodil and ketamine 
are examples of non-competitive NMDAR antagonists. Ifenprodil binds to the GluN2B 
subunit (active site) of NMDARs, whereas ketamine binds to the allosteric site of the channel 
(Orser et al., 1997). Uncompetitive antagonists normally vary from competitive and non-
competitive antagonists because they require a prior receptor activation and can bind to 
diverse allosteric binding sites. Memantine, which is clinically used to treat advanced 
Alzheimer's disease, and MK801, which is used in scientific research only, are prominent 
examples of uncompetitive antagonists and block opened NMDAR channels (Lipton, 2004).  
Some NMDAR antagonists can cross-react with other neuronal ion channels. Memantine and 
MK801 were found to cross-react with α-7-nicotinic acetylcholine and serotonin receptors in 
heterologous expression systems and rat hippocampal neurons (Aracava et al., 2005; Iravani 
et al., 1999; Rammes et al., 2001). Memantine also cross-reacts with dopaminergic (D2) 
receptors in pituitary cells (Seeman et al., 2008). Ifenprodil blocks K+ inward rectifier 
channels (Kobayashi et al., 2006) and ionotropic serotonin receptors (Barann et al., 1998).  
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1.7 GluRs in immune cells 
In recent years it has become more obvious that there is a substantial cross-talk between the 
nervous and immune system. The neuronal chemical synapse and the immunological synapse 
show similarities in their structure and function and neuronal proteins have been detected in 
immune cells and vice versa (Boldyrev et al., 2005; Ganor and Levite, 2014). As the function 
of these proteins in their 'odd' cell types is largely unknown, it is highly interesting to 
understand how for instance 'neuronal' proteins act in lymphocytes. 
Besides the CNS, NMDAR expression has been detected in the heart, kidney, bone, and 
pancreas (Anderson et al., 2011; Bozic and Valdivielso, 2015; Chenu et al., 1998; Genever et 
al., 1999; Inagaki et al., 1995). The expression of NMDAR subunits (GluN1-GluN3B), 
AMPARs (GluR1-GluR3), KA receptors  (KA1-KA2), and mGluRs (mGluR1-8) was found 
in 12 human cancer lines and human skin fibroblasts (Ganor and Levite, 2014). Interestingly, 
AMPARs (GluA3 subunit) (Ganor et al., 2003), group I mGluRs and NMDARs were also 
shown to be expressed in human PBLs (peripheral blood lymphocytes) and leukemic Jurkat T 
cells (Lombardi et al., 2001; Miglio et al., 2005). For murine cells, GluR mRNAs were 
detected in DN, DP and mature thymocyte subsets (Affaticati et al., 2011). Macrophages, 
neutrophils, DCs, and T cells were shown to release Glu (Affaticati et al., 2011; Pacheco et 
al., 2006) and Glu is found in lymphoid tissue and in blood (20-100 µM). Thus, it is attractive 
to conceive that GluRs have an important co-stimulatory role in lymphocyte function. Indeed, 
several groups reported a modulation of immunological responses through GluRs by applying 
different types of GluR antagonists (Ganor and Levite, 2014). 
Glu-activated AMPARs in human T cells induced integrin-mediated adhesion to laminin and 
fibronectin (Ganor et al., 2003; Miglio et al., 2007). GluR3 was found to be expressed in T 
cells of multiple sclerosis (MS) patients and enhanced the proliferation of autoreactive T cells 
in response to myelin basic protein and myelin oligodendrocyte glycoprotein. In addition, 
GluR3 increased the chemotactic migration of T cells towards the chemokine CXCL12/SDF-
1α (Sarchielli et al., 2007). In human lymphocytes, NMDARs were shown to be involved in 
the release of store-operated Ca2+ and the activation of Erk- and PKC-dependent signalling, 
which were inhibited in the presence of NMDAR inhibitor MK801 (Zainullina et al., 2011). 
In murine lymphocytes, NMDARs were found to increase intracellular Ca2+-levels and the 
production of reactive oxygen species (ROS) (Boldyrev et al., 2004). The most 
comprehensive study on NMDARs in murine cells was performed by the Affaticati group. 
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They showed GluN1 localization in the immunological synapse formed between OT-II TCR 
transgenic (tg) thymocytes and DCs presenting cognate OVA (ovalbumin)-peptide. Addition 
of the NMDAR antagonists MK801 or memantine altered the duration of TCR-induced Ca2+-
flux and the apoptosis of DP thymocytes (Affaticati et al., 2011).   
1.8 Aims of the study 
The expression of functional NMDARs had been reported for human T cells, whereas the 
information on NMDARs in murine T cells was scarce when I started the thesis project. A 
potential function of NMDARs in B cells had not been addressed at all. Using Glu as a 
stimulating agent, in some publications it was not evident whether the described effects on T 
cells were due to mGluRs or iGluRs. Furthermore, the described influence of NMDAR 
antagonists on T-cell function was very exciting and opened the question how NMDAR 
activity would integrate into the T-cell signalling network.   
Hence, the major aims of my studies were:  
1)  to prove the expression of NMDARs in murine T and B lymphocytes  
2)  to determine the influence of NMDARs on T- and B-cell activation and proliferation 
3)  to assess how NMDARs affect TCR-, BCR- and LPS/TLR4-induced signalling.   
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2. Material and Methods 
2.1 Material 
2.1.1 Cell culture material and reagents  
RPMI 1640 medium with  
NaHCO3 and stable glutamine and             Biochrom AG (Berlin, Germany) 
10% FCS                  Pan Biotech (Aidenbach, Germany) 
5% glutamine solution    Biochrom AG 
1% sodium pyruvate     Biochrom AG   
100 U/ml penicillin/streptomycin   Biochrom AG 
1% non-essential amino acids                         Biochrom AG 
50 µM β-mercaptoethanol    Gibco, Invitrogen (Darmstadt, Germany) 
FCS was inactivated at 56OC for 50 min, aliquoted and stored at -20OC. Before addition to 
RPMI 1640 medium, the ingredients were sterile-filtered. 
PBS without Ca2+ and Mg2+     Biochrom AG 
IL-4       ImmunoTools (Friesoythe) 
LPS (E. coli 0111:B4)                         Sigma-Aldrich (Taufkirchen) 
phorbol 12-myristate 13-acetate  (PMA)       Calbiochem (Darmstadt)  
ionomycin       Calbiochem  
brefeldin A      Calbiochem 
monensin       Calbiochem 
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2.1.2 Antibodies (Abs) 
2.1.2.1 Abs for cell stimulation 
CD3ε (145-2C11)          BD Biosciences (Heidelberg)  
CD28 (37.51)                       BD Biosciences 
IgM F(ab’)2 (α-IgM)                 Jackson Immunoresearch (Hamburg) 
CD40        Biolegend (San Diego, USA) 
2.1.2.2 Abs for Western blot 
Primary Abs: 
phospho-PLCγ1Y783               (rabbit polyclonal) Cell Signalling (Frankfurt) 
phospho-SrcY418             (rabbit polyclonal) Cell Signalling 
phospho-mTORS2448      (rabbit polyclonal) Cell Signalling 
phospho-AktS473                     (rabbit polyclonal) Cell Signalling  
phospho-Erk1/2T202/Y204    (rabbit polyclonal) Cell Signalling 
phospho-GSK3βSer9                 (rabbit polyclonal) Cell Signalling 
phospho-S6S240/244          (rabbit polyclonal) Cell Signalling 
NFATc1 (7A6)                 (mouse monoclonal) Alexis Biochemicals (Lörrach, Germany)
     
actin                               (mouse monoclonal)  Sigma-Aldrich  
lamin B                           (goat polyclonal) Santa Cruz (Santa Cruz, USA) 
NMDAR1/GluN1            (mouse polyclonal) Synaptic systems (Göttingen) 
       Alomone Labs (Jerusalem, Israel) 
Secondary Abs: 
peroxidase-conjugated AffiniPure goat anti-mouse IgG (H+L)  Jackson Immunoresearch  
peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H+L) Jackson Immunoresearch  
peroxidase-conjugated AffiniPure rabbit anti-goat IgG (H+L) Jackson Immunoresearch 
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2.1.2.3 Abs for flow cytometry  
NMDAR1/GluN1                 Synaptic Systems or Alomone Labs 
IL-10-PE      eBiosciences (Frankfurt) 
IFN-γ-FITC       eBiosciences 
IgG2b-PE      eBiosciences 
IgG2b-FITC       eBiosciences 
anti-rabbit IgG (H+L)-PE (donkey polyclonal) Jackson Immunoresearch 
anti-mouse IgG (H+L)-FITC (goat polyclonal ) Jackson Immunoresearch 
2.1.3 Radioactive material 
3[H]-Thymidine     MP Biomedicals (Heidelberg)  
2.1.4 Inhibitors 
ifenprodil      Tocris Biosciences (Bristol, UK) 
memantine      Tocris Biosciences 
MK801      Tocris Biosciences 
D-APV      Tocris Biosciences 
2.1.5 Chemicals and kits 
37% acetic acid     Sigma-Aldrich 
agarose       Applichem 
40% acryl amide     Roth (Karlsruhe) 
ammonium persulfate (APS)     Sigma (Munich) 
bovine serum albumin (BSA)    Sigma 
BCA protein assay kit     Pierce, Thermo scientific (Bonn) 
chloroform       Roth (Karlsruhe) 
  
  
  Material and Methods 
 
 
28 
 
complete protease inhibitor     Roche (Mannheim) 
diethylpyrocarbonate (DEPC)   Sigma-Aldrich 
dimethyl sulfoxoide (DMSO)    Sigma 
dithiothreitol (DTT)      Sigma               
ethylene glycol tetraacetic acid (EGTA)           Sigma 
ethylene diamine tetraacetic acid (EDTA)   Sigma 
enhanced chemiluminescence (ECL)   Thermo scientific (Karlsruhe) 
ethanol       Roth 
ethidium bromide      Roth 
First Strand cDNA synthesis kit   Thermo scientific 
glycine       Roth 
Gene Ruler™ 100 bp Ladder     MBI Fermentas 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic  
acid (HEPES)       Sigma 
isopropanol       Roth 
lauryl maltoside  (LM)    Calbiochem  
magnesium chloride (MgCl2)    Roth 
milk powder       Roth 
methanol       Roth 
NP-40        Sigma 
phenylmethylsulfonylfluoride (PMSF)  Sigma-Aldrich 
potassium chloride (KCl)    Sigma 
Proteinase K        Sigma-Aldrich 
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protein standard marker (10-170 kDa)  Fermentas 
roti-load 1 (4x)      Roth 
sodium chloride (NaCl)             Roth 
sodium azide (NaN3)     Sigma 
sodium  dodecylsulfate (SDS)    Roth 
sodium orthovanadate (Na3VO4)   Sigma-Aldrich 
sodium fluoride (NaF)    Sigma-Aldrich 
sodium pyrophosphate (Na4O7P2)   Sigma-Aldrich 
tetramethylethylenediamine (TEMED)   Sigma 
TRIS        Roth 
Trypan blue       Sigma 
TRIzol       Life Technologies (Darmstadt)  
Triton-X100       Roth  
Tween 20                Roth 
2.1.6 Miscellaneous material 
1.5 ml reaction tubes      Eppendorf (Hamburg) 
6-, 12-, 96-well plates     TPP (Trasadigen) 
Elisa 96-well plates      Nunc Maxisorp, Thermo Fisher- 
       Scientific (Marietta, USA)   
15, 50 ml tubes      Greiner (Frickenhausen)  
75, 175 cm2 cell culture flasks    Corning Inc. (Wiesbaden) 
Cuvettes 50-2000 µl (UVette 220-1600 nm)  Eppendorf (Hamburg) 
cell scraper       Corning Inc.  
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cell strainer 100 µm Nylon BD FalconTM   BD Biosciences  
5, 10, 25 ml pipettes     TPP 
FACS tubes      BD Biosciences 
FUJI MEDICAL X-RAY FILM-100 NIF  M. Hartenstein (Würzburg)  
nitrocellulose (HybondTM-C Extra)    Amersham Biosciences  
Whatman filter paper      Hartenstein 
Pasteur pipettes      Roth  
PCR tubes      Neolab (Heidelberg) 
syringe filters (0.22 µm)     TPP  
2.1.7 Instruments 
autoMACS       Miltenyi Biotech (Bergisch Gladbach)  
agarose gel electrophoresis chamber    Bio-Rad (Munich) 
balance 440-47N     Kern & Sohn GmbH  (Balingen-         
       Frommern) 
centrifuge 5415D (table centrifuge)    Eppendorf (Hamburg) 
centrifuge Micro 200R (table centrifuge)   Hettich (Tuttlingen) 
centrifuge Multifuge 3S-R     Heraeus (Hanau) 
CO2  incubator      Binder (Tuttlingen) 
ELISA plate reader                                                     Sunrise, Tecan, Männedorf, Switzerland 
film developing machine        CAWO GmbH (Schrobenhausen) 
flake ice machine      Thermo Electron Corporation (Erlangen) 
gel documentation station Win32   Herolab (Wiesloch) 
liquid scintillator 1450 Microbeta    Wallac Perkin Elmer (Turku) 
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magnetic stirrer      IKA (Staufen) 
microwave       AEG (MICROMAT) (Halstenbenk) 
Microscope Axioskop 2 plus    Zeiss (Jena) 
PCR machine T3000 Thermocycler    Biometra (Göttingen) 
PHD cell harvester      Inotech (Nabburg) 
photo scanner perfection 4990   Epson (Meerbusch) 
pH meter       Ino lab (Weilheim) 
precision balance      OHAUS (Nänikon) 
RC-5 super speed refrigerated centrifuge  Kendro Laboratory (Langenselb) 
safety cabinet       Heraeus (Hera Safe HS 12) (Hanau) 
shaker Duomax 1030     Heidolph (Kelheim) 
spectrophotometer 3000     Biometra  
thermomixer       Eppendorf  
transilluminator      Messinstrumentebau (Erlangen) 
vortex       IKA®-Labortechnik (Staufen) 
Neubauer chamber      Roth  
BD LSR Fortessa     BD Biosciences  
water bath      GFL (Burgwegel) 
2.1.8 Software 
FlowJo v3.6.1      TreeStar (Ashland, USA) 
Cell-Quest pro      BD Biosciences  
1D 3.6 Image Quant      Kodak  
Graphpad Prism 3.02      GraphPad Prism Inc. (CA, USA)  
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2.1.9 Mouse lines 
C57BL/6 wildtype (wt)  bred at Animal Facilty, Medical Faculty, Magdeburg, 
GluN1flx/flx                provided bv Prof. R. Sprengel, Max-Planck-Institute for  
               Medical Research, Heidelberg, Germany (Schwenk et al., 1995) 
CMV-Cre deleter   provided bv Prof. R. Sprengel (Sprengel and Single, 1999) 
IL-10 GFP knock-in-tiger     provided by Prof J. Hühn, HZI Braunschweig, Germany  
    (Kamanaka et al., 2006) 
All mice used in this study were on C57/BL6 background and 6-12 weeks or 16 weeks of age 
or were used as newborns within 8 hours after birth. Mice were bred at the Animal Facility of 
the Medical Faculty of the Otto-von-Guericke-University Magdeburg under pathogen-free 
conditions. All animal work was performed in compliance wih the German and local 
guidelines for the Use of Experimantal Animals. 
2.2 Methods 
2.2.1 Isolation of immune cells 
2.2.1.1 Isolation of thymocytes, spleen and lymph node cells 
Mice were sacrificed by CO2 and thymus, spleen or lymph nodes were extracted and kept in 
supplemented RPMI medium at room temperature (RT). Organs were gently rubbed with a 
plastic syringe through a plastic cell strainer to obtain single cell suspensions in complete 
RPMI medium. An aliquot of cells was diluted with 0.1% Trypan blue in PBS to determine 
the cell concentration with a Neubauer cell-counting chamber. 
2.2.1.2 Isolation of CD4+ T cells 
Abs for cell isolation: 
biotin anti-mouse CD8 (53-6.7)               BD Biosciences 
biotin anti-mouse I-A/I-E (2G9)         BD Biosciences 
biotin anti-mouse CD45R/B220 (RA3-6B2)        BD Biosciences  
biotin anti-mouse TER-119/erythroid cells (Ly-76)     BD Biosciences  
streptavidin micro beads           Miltenyi Biotech  
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Running buffer:  
500 ml  1x PBS without Ca2+ and Mg2+ 
10%    BSA 
2 mM   EDTA 
Isolation of CD4+ T cells was done by negative selection using AutoMacs technology 
(Miltenyi Biotech). Lymphocyte single cell suspensions were centrifuged at 1300 rpm (330 g 
Heraeus Multifuge 3S-R) for 5 min at 4OC. The supernatant was discarded and cells were 
suspended in running buffer (100 µl buffer for 1x107 cells). A cocktail of depletion Abs was 
added to the cell suspension (0.2 µl of each Ab for 1x107 cells) and cells were incubated for 
20 min at 4OC (gentle mixing with fingers was performed in between). Running buffer (2 ml 
for 1x107 cells) was added for washing the cells. Samples were centrifuged at 1300 rpm for 5 
min at 4OC and the cell pellet was suspended in running buffer containing streptavidin beads 
(90 µl running buffer, 10 µl of streptavidin beads for 1x107 cells). After gentle inversion of 
the tubes, cells were incubated for 15 min at 4OC. Running buffer (2 ml of buffer for 1 x 107 
cells) was added and cells were centrifuged. The cell pellet was suspended in 1 ml running 
buffer for 1x108 cells and to get rid of clumps, the cells were strained through a plastic cell 
strainer (100 µm) into a new Falcon tube. The isolation of CD4+ T cells was performed using 
an AutoMacs machine and selection of the ‘Deplete’ program. Cells were collected at the 
negative port of the Auto Macs. Isolated CD4+ T cells were spun down at 1450 rpm (450 g 
Heraeus Multifuge 3S-R) for 7 min at 4OC, the supernatant was discarded cells were 
suspended in supplemented RPMI medium and counted for further experimentation. 
2.2.1.3 Isolation of B cells 
B cell isolation kit from Miltenyi Biotech 
 
Gey’s solution: 
Stock solution A:    Stock solution B:   Stock solution C: 
35 g NH4Cl     0.42 g MgCl2, 6 H2O   2.25 g NaHCO3 
1.85 g KCl     0.14 g MgSO4, 7H2O             add 100 ml ddH2O 
1.5 g Na2HPO4, 2 H2O              0.34 g CaCl2 
0.12 g KH2PO4               add 100 ml ddH2O 
5 g glucose 
add 1000 ml ddH2O 
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Final Gey’s solution (100 ml): A+ B+ C+ ddH2O = 20 ml+ 5 ml+ 5 ml+ 70 ml 
Spleens of sacrificed mice were taken and kept in supplemented RPMI medium at RT. The 
spleen was gently rubbed through a plastic cell strainer (100 µm) with a plastic syringe to 
obtain a single cell suspension. Cells were centrifuged at 1300 rpm (330 g Heraeus Multifuge 
3S-R) for 5 min at RT, the supernatant was discarded and cells were resuspended with 37OC 
warm Gey’s solution (3 ml for 1 spleen) for lysis of erythrocytes. Cells were again 
centrifuged for 5 min at 1300 rpm at RT. Cells were taken up in complete RPMI medium and 
the cell number was determined with 0.1% Trypan blue in PBS and a Neubauer counting 
chamber. 
The isolation of B cells was done by negative selection using a B cell isolation kit and 
AutoMacs technology. Splenic cells were centrifuged at 1300 rpm for 5 min at 4OC. The 
supernatant was discarded and cells were suspended in 40 µl running buffer/1x107 cells. From 
the provided Ab cocktail, 5 µl Ab cocktail/1x107 cells was added and cells were incubated for 
15 min at 4OC with gentle mixing in between. Thereafter, 30 µl of running buffer and 10 µl of 
streptavidin beads/1x107 cells were added and after gentle inversion of tubes, cells were 
incubated for 15 min at 4OC. After addition of 2 ml of running buffer/1 x 107 cells and 
centrifuged at 1300 rpm for 5 min at 4OC. The cell pellet was suspended in 1 ml running 
buffer/1x108 cells and cells were strained through a plastic cell strainer (100 µm) to remove 
clumps. The last two steps were repeated to recover all cells. The isolation of B cells was 
performed with the AutoMacs machine using the ‘Deplete S’ program. Negatively selected B 
cells were collected and spun down at 1450 rpm (450 g Heraeus Multifuge 3S-R) for 7 min at 
4OC. B cells were suspended in complete RPMI medium and the cell number was determined 
for further experimentation. 
2.2.2 Isolation of RNA and RT-PCR 
Freshly isolated or cultured CD4+ T cells or B cells were centrifuged at 1300 rpm (330 g 
Heraeus Multifuge 3S-R) for 5 min at RT. The supernatant was discarded and 1 ml of TRIzol 
reagent for 1x107 cells was added to the cell pellet. Cells were quickly lysed by pipetting up 
and down and the suspension was stored at -20OC or RNA phase separation was performed. 
For this, the suspension was kept at RT for 5 min, 200 µl of chloroform/1 ml of TRIzol 
reagent was added, the tube was vigorously shaken by hand for a few seconds and then 
incubated for 3-10 min at RT. The sample was centrifuged at 13000 rpm for 15 min at 4OC. 
The aqueous phase (upper layer) was collected without disturbing the lower phase and 
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transferred into a new Eppendorf tube. 500 µl of isopropanol/1x107 cells was added to the 
aqueous phase, the solution was mixed and incubated for 10 min at RT. Thereafter the 
solution was centrifuged at 13000 rpm for 15 min at 4OC. The supernatant was discarded and 
the RNA pellet was washed with 1 ml 75% ethanol/1x107 cells by vortexing for a few seconds 
followed by centrifugation at 13000 rpm for 15 min at 4OC. The supernatant was discarded 
and the above wash step was repeated. The RNA pellet was dried at RT for a few minutes and 
RNA was suspended in RNAse free DEPC H2O. The RNA concentration was determined 
with a spectrophotometer. 1 µg of RNA was used for cDNA synthesis using the First-strand 
cDNA synthesis kit (Thermo Scientific) manufacturer’s protocol. The cDNA was used for 
PCR analysis. 
2.2.2.1 PCR primers and RT-PCR reaction 
PCR primers for: 
GluN1 
Forward: 5`-TGTGTCCCTGTCCATACTCAAG-3´ 
Reverse:  5`-GTCGGGCTCTGCTCTACCACTC-3´     
GluN2A 
Forward: 5`-GGAGAAGG GTACTCCAGCGCTGAA-3´ 
Reverse:  5`-AGTCTGTGAGGAGATAAAAT CCAGC-3´   
GluN2B 
Forward: 5`-GCAAGCTTCTGTCATGCTCAACATC-3´ 
Reverse:  5`-GCTCTGCA GCTTCTTCAGCTGATTC-3´ 
GluN2D 
Forward: 5`-CTTGGCTCCTCCACAGAGCAACAGC-3´ 
Reverse:  5`-CCTCTTCTGCCGCCCGGAAAACAGG-3´ 
IL-10 
Forward: 5`-TGCCTTCAGTCAAGTGAAGACT-3´  
Reverse:  5`-AAACTCATTCATGGCCTTGTA-3´ 
GAPDH 
Forward: 5`-CAAGGTCATCCATGACAACTTTG-3´ 
Reverse:  5`-GTCCACCACCCTGTTGCTGTAG-3´ 
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Actin 
Forward: 5`-CCAGGTCATCACTATTGGCAAGGA-3´ 
Reverse:  5`-GAGCA GTAATCT CCTTCTGCATCC-3´ 
All PCR primers were purchased from APARA Bioscience (Jena, Germany), Taq polymerase 
and other PCR regents were obtained from Promega (Madison, USA). 
RT-PCR reaction 
GluN1 RT-PCR 
PCR components    concentration           quantity  
cDNA      0.5-1 µg     x µl  
forward primer    10 µM   0.4 µl 
reverse primer     10 µM   0.4 µl 
dNTPs      10 mM   0.4 µl 
MgCl2      25 mM   2.0 µl 
5 x Go green reaction buffer   5 x   4.0 µl 
Taq DNA polymerase    5U/µl   0.1 µl 
DEPC H2O       -            12.7 µl 
PCR program: 
1. initial denaturation   94OC  5 min 
2. denaturation    94OC  1min   
3. annealing    61OC  1 min 45 cycles 
4. elongation    72OC  1 min 
5. elongation    72OC  5 min 
6. pause      4OC    ∞ 
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 RT-PCR for NMDAR subunits, IL-10 and GAPDH: 
             PCR   annealing temp. cycles expected size of 
PCR fragment 
GluN2A 
GluN2B 
GluN2D 
          IL-10 
GAPDH 
54OC 
67OC 
57OC 
60OC 
58OC 
40 
40 
45 
40 
30 
280 bp 
220 bp 
298 bp 
346 bp 
496 bp 
 
2.2.3 Isolation of DNA 
DNA isolation buffer (tail lysis buffer) 
  50 mM    Tris, pH 8.0   
100 mM  EDTA   
100 mM   NaCl   
1%          SDS 
in ddH2O 
Isolated thymocytes were centrifuged at 1300 rpm for 5 min at 4OC. Cells were lysed in 400 
µl tail lysis buffer/1x106 cells supplemented with 10 µl Proteinase K (20 mg/ml) for 10-20 
min at 55OC and shaking at 500 rpm. 400 µl isopropanol was added and after mixing the 
DNA was fished with a moulded glass Pasteur pipette. The Pasteur pipette tip with the 
attached DNA was dried at RT for a few minutes and sprayed with 70% ethanol for DNA 
washing. After air drying the Pasteur pipette tip was broken into 200 µl ddH20 in Eppendorf 
tube. The DNA was dissolved from the broken glass tip by incubation at 60OC for 20 min and 
500 rpm rotation. The DNA concentration was determined by spectrophotometer and DNA 
was used for immediate PCR reactions or stored at -20OC.    
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2.2.3.1 PCR of genomic DNA 
Primers for:       
GluN1flx 
P1-forward: 5`-CTGGGACTCAGCTGTGCTGG-3´ 
P2-reverse:  5`-AGGGGAGGCAACACTGT GGAC-3´      
GluN1 deletion 
P3-forward: 5`-GAGAAAGACATGGGGCATTATCC-3´ 
P2-reverse:  5`-AGGGGAGGCAACACTGT GGAC-3´ 
CMV-Cre  
Forward: 5`-ACGACCAAGTGACAGCAATG-3´ 
Reverse:  5`-CTCGACCAGTTTAGTTACCC-3´ 
Actin 
Forward: 5`-CCAGGTCATCACTATTGGCAAGGA-3´ 
Reverse:  5`-GAGCAGTAATCTCCT TCTGCATCC-3´ 
 PCR for GluN1flx and GluN1wt alleles 
 PCR components           concentration           quantity  
 genomic DNA    0.5-1 µg     x µl   
 P1-forward      10 µM   1.0 µl 
 P2-reverse      10 µM   1.0 µl 
 dNTPs     10 mM   0.4 µl 
 MgCl2      25 mM   2.0 µl 
 5x Go green reaction buffer    5x   4.0 µl 
 Taq DNA polymerase   5U/µl   0.1 µl 
 DEPC ddH2O             -   9.5 µl 
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PCR programme: 
1. initial denaturation   95OC  5 min 
2. denaturation    95OC  1 min    
3. annealing    58OC  30 sec  35 cycles 
4. elongation    72OC  50 sec 
5. elongation    72OC  5 min 
6. pause      4OC    ∞ 
PCR for GluN1 deletion 
PCR annealing 
temp. 
cycles expected size of PCR 
fragment 
GluN1 deletion 
(deletion of GluN1 exons 11-18; P3, 
P2 primers) 
CMV-Cre tg 
actin 
58OC 
 
60OC  
58OC 
35 
 
34 
30 
780 bp 
 
 350 bp 
 240 bp 
 
2.2.4 Agarose gel electrophoresis 
50 x TAP                
242 g      Tris     
57.1 ml   37% acetic acid   
37.2 g    EDTA (titration complex 3) 
add 1000 ml ddH2O, pH 8.0  
1% agarose gel 
100 ml  1x TAP 
1 g   agarose 
10 mg/ml  ethidium bromide 
Gene Ruler™  100 bp ladder  
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1% agarose was added to 1 x TAP buffer, the mixture was boiled in a microwave and 10 µl 
ethidium bromide was added before casting the agarose into a gel chamber. 10 µl of the PCR 
samples were loaded onto the gel agarose, which was run at a constant voltage of 100 V for 
25-30 min. PCR DNA fragments were visualized under an UV gel documentation system 
(Herolab) and the size of PCR products was identified by the Gene ruler 100 bp ladder.   
2.2.5 Proliferation assay 
2.2.5.1 T-cell proliferation 
Thymocytes or CD4+ T cells (0.5-1x105) were stimulated with plate-bound CD3 Abs (3 or 10 
µg/ml) or CD3+CD28 Abs (3 and 5 µg/ml) in the presence or absence of NMDAR inhibitors 
in complete RPMI 1640 medium/10% FCS in triplicates in 96-well plates. 3[H]-Thymidine 
(0.2 µCi/well) was added after 24 h of culture for 16 h. Cells were harvested using a PHD cell 
harvester (Inotech) and incorporated 3[H]-Thymidine was determined with liquid scintillation 
counting using a liquid scintillator 1450 Microbeta Wallac machine (Perkin Elmer). 
2.2.5.2 B-cell proliferation 
Splenic B cells (0.5-1x105) were stimulated with soluble α-IgM or LPS (10 µg/ml). Cells 
were cultured in the presence or absence of NMDAR inhibitors in complete RPMI 1640 
medium/10% FCS in triplicates in 96-well plates. 3[H]-Thymidine (0.2 µCi/well) was added 
after 24 h. 3[H]-Thymidine incorporation was determined as described for T cells.  
2.2.6 Western blot analysis 
10 x electrophoresis buffer                
0.25 M  Tris base 
1.92 M  glycine 
1%   SDS (w/v) 
in ddH2O 
10 x blotting buffer                           
1.92 M   glycine 
0.25 M  Tris Base 
   20 %  methanol 
in ddH2O 
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10 x TBS                              
25 mM           Tris base 
137 mM        NaCl 
in ddH2O 
1 x TBST or wash buffer              
10%             10 x TBS 
0.05%  Tween-20 
in ddH2O 
blocking buffer                           
1 x  TBST 
5%  milk powder (w/v) 
4 x upper gel buffer (UGB)     
0.5 M   Tris 
0.4%   SDS (w/v) 
in ddH2O, pH 6.8 
4x lower gel buffer (LGB)               
1.5 M   Tris 
0.4%   SDS (w/v) 
in ddH2O, pH 8.8 
SDS 8% polyacrylamide gel electrophoresis (PAGE) gel 
11 ml    ddH20     
  5 ml    40% acryl amide   
  5 ml    4 x LGB buffer   
66 µl    10% APS 
20 µl     TEMED 
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SDS 10% PAGE gel 
10 ml    ddH20     
  5 ml    40% acryl amide   
  5 ml    4 x LGB buffer   
66 µl    10% APS 
20 µl     TEMED 
SDS PAGE stacking gel 
5.5 ml   ddH20     
1.3 ml   40% acryl amide   
5.0 ml   4 x UGB buffer   
 33 µl    10% APS 
 20 µl    TEMED 
2.2.6.1 Preparation of total protein cell extracts 
NP-40 lysis buffer 
       1%  NP-40                                                         
100 mM  NaCl           
  50 mM  HEPES pH 7.4 
    5 mM  EDTA 
  50 mM  NaF   
Added freshly before use: 
10 mM   sodium pyrophosphate 
     1%       lauryl maltoside  (LM)                    
 1 mM   phenylmethylsulfonylfluoride (PMSF) 
 1 mM   sodium orthovanadate 
     1 x   complete protease inhibitor        
Protein extracts were prepared from thymocytes or lymph node CD4+ T cells, B cells or total 
brain. Single cell suspensions were washed once with 1 ml ice-cold PBS and centrifuged for 5 
min at 1300 rpm. The cell pellet was lysed with ice-cold lysis buffer (100 µl for 1x107 cells) 
and lysates were vortexed and incubated on ice for 30 min. Thereafter, lysates were 
centrifuged at 14000 rpm for 20 min at 4OC. Supernatants were transferred into 1.5 ml 
Eppendorf tubes and used as total protein cell lysates. The protein concentrations were 
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determined by BCA protein assay kit. 1/4 volume of 4 x Roti-Load was added to the lysates 
which were boiled at 95OC for 5 min and shaking at 500 rpm. Protein samples were stored at -
20OC. LM in the cell lysis buffer led to the disruption of membrane lipid rafts. 
2.2.6.2 Preparation of cytoplasmic and nuclear protein extracts 
Cytoplasmic protein extract (CE) buffer: 
10 mM  KCl 
10 mM  HEPES, pH 7.9 
0.1 mM  EGTA, pH 7.9 
0.1 mM  EDTA, pH 7.9 
Added freshly before use: 
1 mM   DTT 
1 mM   sodium orthovanadate 
    1 x   complete protease inhibitor 
Nuclear protein extract (NE) buffer: 
420 mM   NaCl 
  20 mM       HEPES, pH 7.9 
 0.1 mM  EGTA, pH 7.9 
 0.1 mM  EDTA, pH 7.9 
Added freshly before use: 
1 mM   DTT 
1 mM   sodium orthovanadate 
    1 x   complete protease inhibitor 
CD4+ T cells or B cells (5x106) were harvested and washed once with 1 ml ice-cold PBS and 
centrifugation at 7500 rpm for 1 min at 4OC. Cells were lysed with ice-cold CE buffer (70 µl 
for 1x107 cells) and incubated for 2 min on ice. The solution was supplemented with 0.5% 
NP40 and incubated for 2 min on ice and was gently vortexed for a few seconds to get a 
transparent clear solution. The sample was centrifuged for 3 min at 14000 rpm and 4OC, the 
collected supernatant was transferred into a new 1.5 ml Eppendorf tube and used as 
cytoplasmic protein extract (CE). The transparent pellet containing the nuclei was washed 
with ice-cold CE buffer (800 µl for 1x107 cells) without disturbing the pellet and again 
centrifuged for 3 min at 14000 rpm and 4OC. The supernatant was discarded and the wash 
  
  
  Material and Methods 
 
 
44 
 
step was repeated. Afterwards ice-cold NE buffer (35 µl for 1x107 cells) was added to the 
pellet, the Eppendorf tube was vortexed for a few seconds and kept on a rotating wheel at 4OC 
for over night. The next day the sample was centrifuged for 20 min at 14000 rpm and 4OC. 
The supernatant containing nuclear proteins was transferred into a 1.5 ml Eppendorf tube and 
used as nuclear protein extract (NE). Protein concentrations in CE and NE were determined 
with BCA protein assay kit. 1/4 volume of 4 x Roti-Load was added to the prepared lysates 
which were boiled at 95OC for 5 min and shaking at 500 rpm. CE and NE were stored at -
20OC until use in Western blot. 
2.2.6.3 SDS PAGE and Western blot 
Protein lysates obtained from CD4+ T cells (5-15 µg), thymocytes (20 µg), B cells (15 µg) or 
brain (5 µg) were subjected to 8-10% SDS-PAGE. Separated proteins were transferred onto a 
nitrocellulose membrane, which was blocked with 5% non-fat milk powder in TBST for 1 h at 
RT and then washed three times for 5 min with wash buffer. The expression/activation of 
signalling proteins was analysed by incubating the membrane with primary Abs in TBST/5% 
BSA for 1 h or over night at 4OC on a shaker. Thereafter, the membrane was washed three 
times for 5 min with wash buffer and incubated with HRP-coupled mouse anti-rabbit, goat 
anti-mouse or donkey anti-goat secondary Abs in TBST/5% milk for 1 h at RT. After three 
washes for 10 min with wash buffer, ECL was added and the membrane was exposed to X-
ray film. For quantification, immune reactive bands on the film were scanned with a photo 
scanner (Epson perfection 4990) and analysed with 1D 3. 6 Image Quant software (Kodak).  
2.2.7 Flow cytometry 
FACS buffer: 0.5% BSA in 1 x PBS without Ca2+ and Mg2+  
FoxP3 staining buffer kit (BD Biosciences) 
To measure intracellular protein expression of NMDAR subunits, ~2 x106 thymocytes or 
lymphnode cells were first stained for surface expression of CD4 and CD8 for 20-25 min at 
RT in FACS buffer. Stained cells were washed with 1 ml PBS and centrifuged at 1300 rpm 
for 5 min at RT. Cells were resuspended in 400 µl fixation and permeabilization buffer 
provided in the FoxP3 staining buffer kit and incubated for 25-30 min at RT. Thereafter 500 
µl permeabilization buffer was added to the fixed cells and cells were centrifuged. The cell 
pellet was taken up in 100 µl permeabilization buffer containing primary Abs directed against 
NMDAR subunits. After incubation for 30 min at RT, 500 µl permeabilization buffer was 
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added and cells were centrifuged. Resuspended cells were stained with secondary 
fluorochrome-coupled anti-rabbit Abs for 30 min at RT. 500 µl permeabilization buffer was 
added, cells were centrifuged and washed once with FACS buffer. Cells were measured with 
a LSR Fortessa and flow cytometric analysis was performed with Cell-Quest pro and FlowJo 
7.6.5 software. 
2.2.8 Intracellular cytokine staining and IL-10-GFP expression assay 
Splenic B cells were stimulated with α-IgM+CD40 (10 +5 µg/ml), CD40 Abs alone (5 µg/ml), 
or LPS (10 µg/ml) for 48 h or 72 h. Ifenprodil (10 µM) was added once and at day 1. Before 
harvest, the cells were treated with IO (800 ng/ml) and PMA (500 ng/ml) for 4 h in the 
presence of Brefeldin A (3 µg/ml).  Thereafter, cells were fixed and stained with IL-10-PE 
and IFN-γ-FITC Abs and isotype controls IgG2b-PE/FITC by using the FoxP3 staining buffer 
kit (eBiosciences) and manufacturer’s protocol. The percentage of live B cells producing IL-
10 or IFN-γ was determined with flow cytometry. B cells isolated from IL-10-GFP tiger mice 
(Kamanaka et al., 2006) were activated with α-IgM/CD40 Abs (10+5 µg/ml) or LPS (10 
µg/ml) and cultured in 96-well plates. Ifenprodil (10 and 20 µM) was added at 21-25 h and 
cells were harvested either at day 2 or day 4. Before harvest, cells were re-stimulated with 
PMA (100 ng/ml) and IO (800 ng/ml) for 4 h in the presence of monensin (10 µg/ml). IL-10 
or IFN-γ production and IL-10-GFP expression in FSC/SSC-gated live B cells was 
determined with flow cytometry.  
2.2.9 ELISA 
B cells were activated with LPS (10 µg/ml) or LPS plus IL-4 (20 ng/ml) in complete 
RPMI/10%FCS medium in triplicates in 96-well plates. Ifenpodil (10 µM) was added at day 1, 
day 2 or at day 3 and culture supernatants were taken at day 4. ELISA plates were coated over 
night with 50 µl goat anti-mouse Ig (Southern Biotech, Birmingham, AL, USA) at 1:500 
dilution in 50 mM sodium carbonate buffer. After washing with PBS/0.05% Tween 20, the 
wells were blocked with PBS/5% BSA for 1 h. The supernatant samples were diluted in 
PBS/5% BSA and incubated in the coated wells for 2 h at RT. After washing, POD-coupled 
anti-mouse IgM or IgG (Sigma-Aldrich) was added at 1:250 dilutions in PBS/5% BSA for 1 h 
at RT, followed by substrate development with TMB reagent (BD Biosciences). The OD at 
450 nm was determined with an ELISA reader (Sunrise, Tecan, Männedorf, Switzerland).  
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2.2.10 Statistical analysis 
The data in graphs are given as mean values + standard deviation (SD), if not stated otherwise. 
Unpaired Student’s t test and other statistics were performed in GraphPad Prism 3.02. 
Statistical significance was set as *p<0.05, **p<0.01 and ***p<0.001. 
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3. Results 
3.1. The function of NMDARs in murine T cells 
3.1.1 Analysis of NMDAR expression in thymocytes and CD4+ T cells 
Previous studies reported the expression of NMDARs subunits in thymocytes and human 
lymphocytes based on RT-PCR and flow cytometry analyses. GluN1 subunit localization in 
the contact zone of murine thymocyte-DC pairs was shown by confocal microscopy 
(Affaticati et al., 2011; Ganor et al., 2003; Lombardi et al., 2001). Thus, I initially performed 
RT-PCR to elucidate mRNA expression of the NMDAR subunits GluN1, GluN2A and 
GluN2B in murine lymphocytes. mRNA was isolated from total thymocytes, naive as well as 
CD3+CD28 Ab-activated peripheral CD4+ T cells and brain, for comparison (Figure 5). 
GluN1, GluN2A and GluN2B mRNAs were found in thymocytes and naive mature CD4+ T 
cells (Figure 5, left panel) and GluN1 mRNA expression was upregulated in CD4+ T cells 
after their stimulation with CD3+CD28 Abs for 24 and 48 h (Figure 5, right panel). In line 
with the publication of Affaticati et al., the RT-PCR results suggested that NMDARs are 
expressed in thymocytes, but also in peripheral naive and activated CD4+ T cells. 
 
Figure 5. RT-PCR analysis of NMDAR subunit mRNA expression. mRNA expression of NMDAR 
subunits GluN1, GluN2A and GluN2B was analysed by RT-PCR in thymocytes, peripheral CD4+ T 
cells and brain (left panel), and GluN1 mRNA expression in CD3+CD28 Ab (3 and 5 µg/ml)-activated 
CD4+ T cells at the indicated time points in comparison to brain (right panel). Actin or GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) mRNA expression served as RT-PCR control. Data 
are the representative of 2-3 experiments (Kahlfuss et al., 2014).    
Subsequently, experiments were performed to detect protein expression of NMDAR subunits 
in CD4+ T cells. Isolated naive CD4+ T cells were intracellularly stained with GluN1, 
GluN2A and GluN2B Abs (from Alomone Labs) and analysed by flow cytometry (Figure 6). 
The obtained positive stainings for NMDAR subunits indicated protein expression of 
functional NMDARs in CD4+ T cells.  
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Figure 6. Expression of NMDAR subunits in CD4+ T cells at protein level. CD4+ T cells were 
intracellulary stained for GluN1, GluN2A and GluN2B (Abs from Alomone Labs) and analysed by 
flow cytometry. Histograms show NMDAR subunit (black line) and IgG2b isotype (grey line) staining 
and are representative for 3 independent experiments.  
3.1.2. NMDAR antagonists inhibit T-cell proliferation  
Since NMDARs seemed to be expressed in thymocytes and CD4+ T cells, we asked whether 
NMDARs play a role in CD4+ T-cell activation. To address this question, different NMDAR 
antagonists were used to inhibit NMDAR activity during T-cell stimulation. Isolated CD4+ T 
cells were stimulated with high (10 µg/ml) and low (3 µg/ml) concentrations of CD3 Ab in 
the presence or absence of the GluN2B antagonist ifenprodil and the open channel blockers 
MK801 and memantine. As shown in Figure 7, all three inhibitors significantly reduced T-cell 
proliferation in a concentration-dependent manner. Under strong stimulatory conditions with 
10 µg/ml CD3 Ab (Figure 7a), T-cell proliferation was less inhibited by 3-10 µM ifenprodil 
compared to lower CD3 Ab concentrations (3 µg/ml Ab, Figure 7b) indicating that the effects 
of NMDAR antagonism also depend on the strength of T-cell stimulation. 
Consequently, I asked whether the addition of exogenous IL-2 or CD28 co-stimulation would 
abrogate or milden the inhibitory effects of NMDAR antagonists on T-cell proliferation. 
Indeed, in the presence of IL-2 or under CD28 co-stimulatory conditions NMDAR antagonist 
ifenprodil had a significant lower inhibitory effect on T-cell expansion compared to T cells 
stimulated with CD3 Abs only (Figure 7c). These results indicate that NMDAR-induced 
signals contribute to T-cell activation and that their inhibition impairs T-cell proliferation, 
especially under weak stimulatory conditions or in the absence of CD28 co-stimulation. This 
may result from an altered T-cell signalling and IL-2 production after antagonist addition. 
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a)      b) 
 
                                                                                 
 
 
 
 
 
 
        
c)  
          
Figure 7. NMDAR antagonists block T-cell proliferation. CD4+ T cells were stimulated with a) 
CD3 Abs (10 µg/ml) in the presence or absence of ifenprodil and MK801 in the indicated 
concentrations, b) CD3 Abs (3 µg/ml) in the presence or absence of  ifenprodil and memantine or c) 
CD3 Abs (3 µg/ml) or CD3+CD28 Abs (3 and 5 µg/ml) with or without ifenprodil (50 µM) and IL-2 
(20 U/ml). Proliferation was determined by 3[H]-Thymidine incorporation (cpm) at 24 h. Data show 
the mean + SD cpm of triplicates and are representative for 3 experiments. Significant p values were 
calculated by Student’s t test with *p < 0.05; **p < 0.01; ***p < 0.001 (Kahlfuss et al., 2014).  
3.1.3 GluN1 protein expression in murine T cells is elusive 
Although mRNA for NMDAR subunits was detected by RT-PCR, apparent protein 
expression of NMDAR subunits by intracellular FACS staining, and NMDAR antagonists 
inhibited T-cell proliferation, we could not reliably detect surface expression of NMDAR 
subunits in murine thymocytes or peripheral T cells using two different GluN1 Abs detecting 
extracellular epitopes of GluN1 and standard flow cytometry. To clarify the missing evidence 
of NMDAR surface expression, protein expression of the obligatory GluN1 subunit was 
analysed by Western blot. GluN1 protein in thymocytes (Figure 8a) and CD4+ T cells (data 
not shown) appeared in three distinct immunoreactive bands, with the major band at ~110 
kDa, i.e. at a lower MW than found for GluN1 from total brain cells with ~120 kDa. RT-PCR 
analyses for GluN1 mRNA revealed that the lower MW could result from the detected 
alternative splice forms of GluN1 in murine thymocytes (data not shown). 
Immunopreciptiation experiments to pull down GluN1 subunits from thymocytes or CD4+ T 
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cells were unsuccessful (data not shown). These negative results suggested that the GluN1 
Abs may not detect GluN1 protein in thymocytes and CD4+ T cells and that the Abs used by 
us and others (Affaticati et al., 2011) might be specific for GluN1 in neuronal cells, but not 
for GuN1 in lymphocytes. To clarify this question, I analysed GluN1 knockout (ko) mice, 
which do not express NMDARs due to the loss of the obligatory GluN1 subunit. GluN1 ko 
mice were generated by crossing GluN1flx/flx mice with tg CMV-Cre deleter mice to delete 
GluN1 in all cells (Sprengel and Single, 1999). These mouse lines were kindly provided by 
Prof. R. Sprengel (MPI, Heidelberg). A feature of GluN1 deletion is that newborn mice die 
within hours after birth due to a critical defect of the central respiratory system and loss of the 
sucking reflex. To discriminate GluN1 wildtype (wt) or heterozygous (het) mice from GluN1 
ko mice, newborns were monitored for 6 to 8 h after birth. Wt newborn mice would have 
sucked milk from the mother within that time, but not GluN1 ko newborns, allowing the 
identification of GluN1 ko newborns by the lack of milk in their stomach (Figure 8b).  
a)           b) 
                                        
Figure 8. Analysis of GluN1 protein expression and generation of GluN1 ko mice. a) Western blot 
analysis of GluN1 protein expression (GluN1 Ab from Synaptic Systems) in protein extracts from 
thymocytes and total brain. Actin levels served as a protein loading control. MW markers are 
indicated. b) Strategy to generate GluN1 ko mice by crossing GluN1flx/flx with transgenic (Tg) CMV-
Cre deleter mice. LoxP sites for the excision of exons 11-18 of GluN1 are marked. The photo shows 
newborn mice 6 h after birth. The GluN1 wt/het but not the GluN1 ko mouse shows milk in the 
stomach. 
Besides initial discrimination by stomach milk content, DNA was isolated from GluN1 wt/het 
and GluN1 ko thymocytes and PCR for the floxed GluN1 alleles and the excision of exons 
11-18 of GluN1 was performed (Figure 9a). In addition, mRNA was isolated from the 
respective thymocytes to run RT-PCRs for GluN1 mRNA expression (Figure 9b). In GluN1 
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ko newborns GluN1 deletion was detected at DNA and mRNA level and thus they should not 
express GluN1 protein in thymocytes.  
a)      b) 
 
 
 
 
 
 
 
 
 
Figure 9. Detection of GluN1 deletion in thymocytes. DNA and mRNA were isolated from 
thymocytes and brains of newborn GluN1 ko littermate mice and analysed for GluN1. (a) PCR 
analysis of thymocyte DNA for floxed (+) and wt (-) GluN1 alleles (upper panel) and excision of the 
floxed GluN1 sequence (lower panel). (b) RT-PCR analysis of GluN1 and GAPDH mRNA expression 
in thymocytes and brains of wt and GluN1 ko mice. In (a) and (b), lane 1 represents thymocytes from 
a GluN1 wt mouse and lanes 2-4 thymocytes from GluN1 ko mice (Kahlfuss et al., 2014). 
Protein extracts from thymocytes and the corresponding brains of PCR-typed GluN1 ko and 
wt newborn mice were further used for Western blot analysis. As shown in Figure 10a, GluN1 
protein (~120 kDa) was deleted in brain samples of GluN1 ko mice (Figure10a, brain, lanes 4 
and 5) compared to GluN1 wt mice (Figure10a, brain, lane 6). However, in thymocyte 
samples of the same mice the routinely observed three bands for GluN1 protein in GluN1 
wt/het mice (Figure10a, thymocytes, lanes 1-3 and 6) were still present in GluN1 ko mice 
(Figure10a, thymocytes, lanes 4 and 5). These data strongly suggest that the used GluN1 Ab 
does not detect GluN1 protein in thymocytes but rather cross-reacts with some unknown 
protein. In addition, intracellular FACS staining with two different GluN1 Abs showed an 
identical GluN1 staining in wt and ko thymocytes (Figure 10b, data provided by S. Kahlfuß, 
PhD thesis 2015 (Kahlfuss et al., 2014)). The latter results further support the conclusion that 
the used GluN1 Abs show an unspecific staining in thymocytes.  
Hence, on the protein level, there is no evidence for the expression of the obligatory GluN1 
subunit of NMDARs in murine thymocytes and peripheral T cells. 
 
 
 
GluN1
GAPDH
RT-PCR for GluN1 mRNA
1     2    3    4    ko wt H20
thym.         brain
PCR for GluN1 deletion
PCR for GluN1flx site
1     2     3     4   +/+   -/- H20
1     2     3     4    H20
  
  
  Results 
 
 
52 
 
a)       b) 
 
          
       
 
 
 
 
 
 
Figure 10. Assessment of GluN1 protein expression in GluN1 ko and wt mice. a) Western blot 
analysis was performed for GluN1 protein (GluN1 Ab from Synaptic Systems) in thymocytes and 
brains of GluN1 wt and ko mice. Actin expression served as a control for protein loading. Lanes 4 and 
5 represent GluN1 ko mice, lanes 1-3 GluN1 het mice and lane 6 shows a GluN1 wt mouse. (b) 
Thymocytes from GluN1 wt and GluN1 ko mice were analysed for GluN1 protein expression by 
intracellular FACS staining and flow cytometry. GluN1 Abs were from Synaptic Systems (SySy) or 
Alomone Labs (Alom.). Shaded histograms represent isotype control stainings. Data in b) were kindly 
provided by S. Kahlfuss (Kahlfuss, 2015; Kahlfuss et al., 2014).  
Altogether, the results allow the conclusion that NMDARs are either expressed in very low 
numbers and only transiently come to the cell surface such that the detection methods used by 
us and others are inadequate to conclude their expression in T cells. As mentioned in the 
publication of the Affaticati group (Affaticati et al., 2011), we also could not detect surface 
expression of NMDARs on T cells using whole cell patch clamp analyses (personal 
communication by Dr. T. Bose, LIN, Magdeburg). Thus, the results eventually obtained from 
the analyses of GuN1 ko mice show that protein expression of NMDARs in murine T 
lymphocytes is elusive, if not absent. In view of the obvious effects of NMDAR antagonists 
on T-cell proliferation, we hypothesized that the antagonists cross-inhibit other ion channels 
expressed on lymphocytes.   
To further substansiate this, an important experiment was to determine the proliferation of 
GluN1 ko thymocytes in the presence of NMDAR antagonists (Figure 11). Thymocytes were 
isolated from GluN1 wt and ko newborn mice and stimulated with CD3 Abs (3 µg/ml) in the 
absence or presence of different concentrations of ifenprodil. The proliferation of GluN1 ko 
thymocytes was similar to wt thymocytes in the absence of ifenprodil. Notably, ifenprodil 
inhibited the proliferation of GluN1 ko thymocytes to a similar degree as found for wt 
thymocytes. These results led us to conclude that NMDAR antagonists affect thymocytes and 
T cells not via specific inhibition of NMDARs, but rather by cross-inhibition of other targets. 
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Figure 11. Ifenprodil inhibits the proliferation of GluN1 ko thymocytes. Thymocytes isolated 
from newborn littermate GluN1 ko and GluN1 wt mice (two mice each) were stimulated in triplicates 
with CD3 Abs (3 µg/ml) in the presence of the indicated concentrations ifenprodil. Proliferation was 
determined by 3[H]-Thymidine incorporation at 24 h and is shown as mean + SD relative proliferation. 
Similar results were obtained in 3 experiments.  
Indeed, within our collaborative research project my colleague T. Bose showed in her PhD 
work that the used NMDAR antagonists ifenprodil and memantine cross-inhibit Kv1.3 and 
KCa3.1 potassium channels expressed on T cells and lead to a decrease of Ca2+-flux upon TCR 
stimulation (Kahlfuss et al., 2014; T. Bose, PhD thesis, 2014). For further understanding and 
discussion,  some of her patch clamp results are shown in Figure 12. 
a)                             b) 
           
  
Figure 12. NMDAR antagonists cross-inhibit Kv1.3 and KCa3.1 potassium channels. CD4+ T cells 
were activated with CD3+CD28 Abs (3+5 µg/ml) in the presence of the NMDAR antagonists 
ifenprodil (Ifen.) or memantine (Mem.) and the dose-response relationships for (a) Kv1.3 and (b) 
KCa3.1 channel-mediated currents were determined by whole cell patch-clamp. Inserts show voltage 
ramp protocols and examples of current traces for control conditions and in the presence of 
memantine. Data are normalized to the current measured under control conditions and represented as 
relative inhibition. Data points in the dose-response relationships represent mean values ± SD 
calculated from 5-7 cells each. Data were kindly provided by Dr. T. Bose (Kahlfuss et al., 2014).  
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3.1.4 NMDAR antagonist ifenprodil attenuates TCR-induced signalling  
In the second part of my thesis, I investigated major signalling pathways in antagonist-treated 
lymphocytes in order to gain further understanding of the molecular mechanisms underlying 
the drugs' effects on T-cell activation. Isolated naive CD4+ T cells were stimulated with plate-
bound CD3 Abs (10 µg/ml) in the presence or absence of ifenprodil (50 µM) for 0, 30, 60, 
120, and 240 min. Protein extracts were analysed by Western blot for the activation of the Src 
kinases Lck/Fyn, and serine/threonine kinases Akt and Erk1/2. These short-term stimulation 
assays revealed that ifenprodil impairs the activation of Lck/Fyn, Erk1/2 as well as Akt 
(Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. NMDAR antagonist ifenprodil attenuates TCR signalling. CD4+ T cells were 
stimulated with plate-bound CD3 Abs (10 µg/ml) in the presence or absence of ifenprodil (50 µM) for 
0, 30, 60, 120, and 240 min. Total protein extracts were analysed for the activation of the indicated 
signalling molecules using p-specific Abs and Western blot analysis. Actin expression served as a 
control for protein loading. The indicated numbers give the relative protein expression after 
quantification and normalization to the respective actin controls. Data are the representative of 3 
independent experiments (Kahlfuss et al., 2014).  
As I found that major signalling events in short-term TCR-activated CD4+ T cells were 
attenuated by NMDAR antagonist ifenprodil, it was essential to investigate whether the 
inhibitor would also influence signalling events at later time points. CD4+ T cells were 
stimulated with plate-bound CD3 Abs (3 µg/ml) in the presence or absence of ifenprodil (30 
µM) for 0, 8, 16, and 24 h followed by the analysis of cytoplasmic and nuclear protein 
extracts for the the phosphorylation status of PLCγ1, GSK3β, mTOR, and S6 by Western 
blot. In the presence of ifenprodil, the levels of cytoplasmic pPLCγ1, pGSK3β, pmTOR, and 
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pS6 were significantly reduced compared to untreated cells (Figure 14). These results indicate 
a lower or, in the case of GSK3β, an enhanced activity of these signalling molecules during 
later phases of T-cell activation and thus a long-lasting effect of ifenprodil on PLCγ1- as well 
as Akt-induced signalling events.           
 
 
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. NMDAR antagonist ifenprodil attenuates signalling in long-term stimulated T cells. 
CD4+ T cells were stimulated with plate-bound CD3 Abs (3 µg/ml) in the presence or absence of 
ifenprodil (30 µM) for the indicated time points and cytoplasmic protein extracts were analysed for the 
phosphorylation of PLCγ1, GSK3β, mTOR, and S6 by Western blot. Actin expression served as a 
protein loading control. Indicated numbers give the relative protein expression after quantification and 
normalization to the actin controls. Data are the representative of 3 independent experiments (Kahlfuss 
et al., 2014). 
Several serine protein kinases, including GSK3β, intracellular Ca2+-level and the phosphatase 
calcineurin control NFAT activation. Inactive cytoplasmic NFAT is dephosphorylated by 
calcineurin leading to nuclear localization of NFAT and, among other genes, to the 
transcriptional induction of NFATc1 (Chuvpilo et al., 2002; Hogan et al., 2010). In view that 
NMDAR antagonists reduce TCR-induced Ca2+-mobilization (T. Bose, PhD thesis 2014, 
(Kahlfuss et al., 2014)), it was interesting to determine to what extent ifenprodil impacts on 
NFATc1 activation in long-term stimulated CD4+ T cells. As shown in Figure 15, CD4+ T 
cells stimulated for 24 h in the presence of ifenprodil had a 65% reduction in nuclear NFATc1 
in comparison to cells cultured without drug. Thus, ifenprodil interferes with the maintenance 
of NFATc1 activation, which may contribute to the drug-induced inhibition of proliferation.   
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Figure 15. Ifenprodil reduces nuclear NFATc1 accumulation. Nuclear protein extracts of CD4+ T 
cells stimulated with CD3 Abs (3 µg/ml) for 8, 16 and 24 h in the presence or absence of ifenprodil 
(30 µM) were analysed for NFATc1 expression by Western blot. Lamin B served as a protein loading 
control. Data in the right graph represent the mean relative +SD NFATc1 expression after 
densitometric quantification and relation to Lamin B controls. Data were calculated from 3 
independent experiments. Significance was calculated by Student’s t test with **p < 0.01 (Kahlfuss et 
al., 2014).  
NMDAR antagonist ifenprodil had less inhibitory effects on proliferation when CD4+ T cells 
were co-stimulated with CD3+CD28 Abs (Figure 7c). Thus, I compared the signalling events 
in CD4+ T cells stimulated for 24 h with CD3 Abs alone (3 µg/ml) or with CD3+CD28 Abs 
(3+5 µg/ml) in the presence or absence of ifenprodil (30 µM) (Figure 16). Ifenprodil 
treatment led to a reduced phosphorylation of PLCγ1, GSK3β, mTOR, and S6 in co-
stimulated CD4+ T cells similar to that in CD3 Ab-stimulated  cells. 
 
 
 
 
 
 
 
 
Figure 16. CD28 signals rescue the inhibitory effects of ifenprodil on TCR-induced signalling. 
CD4+ T cells were stimulated with plate-bound CD3 Abs (3 µg/ml) or CD3+CD28 Abs (3+5 µg/ml) 
in the presence or absence of ifenprodil (30 µM) for 24 h and cytoplasmic protein extracts were 
analysed for the indicated proteins by Western blot. Actin expression served as a control for protein 
loading. Indicated numbers give the relative protein expression after quantification and normalization 
to the actin control. Data are the representative of 2 independent experiments (Kahlfuss et al., 2014).  
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However, the level of phosphorylated proteins in co-stimulated T cells was still higher than 
after CD3 stimulation alone and corresponded to that found in CD3 Ab-activated T cells 
cultured without ifenprodil (Figure 16).  
Altogether, the obtained data show that NMDAR antagonist ifenprodil impairs T-cell 
activation by attenuating important TCR-induced signalling events, including the activation of 
Lck/Fyn, PLCγ1, Erk1/2, Akt, S6, and NFATc1. The drug's inhibitory effect, at least partially, 
is overcome by CD28 signals.  
3.2 The effects of NMDAR antagonists on B cells  
B cells are important effectors and regulators of adaptive and innate immune responses by 
providing antigen presentation and co-stimulation for CD4+ T cells, secreting cytokines, and 
production of antigen-specific Abs. By formation of auto-Abs B cells can also mediate 
destructive immune responses as in autoimmune neuroinflammation (Bittner and Meuth, 
2013; Lueg et al., 2015).  
As NMDAR antagonist memantine is in clinical use, it is important to understand the drug’s 
possible side-effects on B cells. Thus, I investigated whether NMDARs are expressed in B 
cells and how NMDAR antagonists affect B-cell signalling, proliferation, IL-10 production, 
and IgM/IgG production. Since B cells can be activated via ligation of the BCR or by 
LPS/TLR4, I used both stimulatory conditions for most experiments.  
3.2.1 Detection of NMDAR subunits in B cells  
 
 
 
 
 
 
 
 
 
Figure 17. RT-PCR analysis detects mRNA of NMDAR subunits in B cells. mRNA expression of 
GluN1, GluN2B and GluN2D subunits in B cells activated with α-IgM (10 µg/ml) or LPS (10 µg/ml) 
for 24 and 48 h and in brain was determined by RT-PCR. GAPDH mRNA expression was used as RT-
PCR control. Data are the representative of 2 experiments. 
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First, B cells were stimulated with α-IgM or LPS for 24 and 48 h and mRNA was isolated 
from the activated B cells. RT-PCR revealed mRNA expression for GluN1, GluN2B and 
GluN2D subunits (Figure 17) suggesting the expression of NMDARs in B cells. However, as 
outlined before for T cells, a reliable detection of GluN1 protein in B cells by Western blot 
was not feasible (data not shown).  
3.2.2 NMDAR antagonists block BCR- and LPS-induced B-cell proliferation  
Kv1.3 channels are expressed on B cells and their inhibition was shown to reduce BCR- and 
PMA/IO-induced B-cell proliferation (Amigorena et al., 1990; Partiseti et al., 1992; Wulff et 
al., 2004). Thus, we suspected that NMDAR antagonists could also affect B cells via cross-
inhibition of Kv1.3 and KCa3.1 channels. 
  α-IgM 
  
 
 
 
 
 
 
         
    
 
Figure 18. NMDAR antagonists inhibit α-IgM-induced B-cell proliferation. Splenic B cells were 
stimulated with α-IgM (10 µg/ml) in the presence or absence of memantine, ifenprodil and D-APV in 
concentrations as indicated. Proliferation was determined by 3[H]-Thymidine incorporation (cpm) at 24 
h. Data in the graphs represent the mean + SD relative proliferation of at least 3 experiments. Significant 
p values were calculated with Student’s t test with *p<0.05, **p<0.01 and ***p<0.001 (Simma et al., 
2014). 
Indeed, my collaborator Dr. T. Bose showed that ifenprodil and memantine, but not D-APV, 
significantly reduce Kv1.3 channel currents on B cells stimulated with α-IgM or LPS. 
Reduced KCa3.1 channel currents were detected only in BCR- but not LPS-activated B cells. 
(data not shown, T. Bose, PhD thesis 2014, (Simma et al., 2014)). Thus, the major targets of 
ifenprodil or memantine in B cells most likely are not NMDARs but Kv1.3 and KCa3.1 
channels.   
First, I investigated the role of NMDARs on B-cell proliferation. Isolated splenic B cells were 
stimulated with IgM F(ab’)2 Abs (α-IgM) (10 µg/ml) to mimic BCR triggering by antigens or 
with the TLR4 ligand LPS (10 µg/ml) in the presence of memantine, ifenprodil or the 
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competitive antagonist D-APV. B-cell proliferation was determined by 3[H]-Thymidine 
incorporation at 24 h. As shown in Figure 18 and Figure 19, memantine and ifenprodil 
significantly inhibited α-IgM- as well as LPS-induced B-cell proliferation in a concentration 
dependent manner. In contrast, even the highest concentrations of D-APV (300 µM) had no 
effect on B-cell proliferation. The latter underlines that the anagonists do not act on NMDARs, 
but through inhibition of other channels. 
 
   LPS 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. NMDAR antagonists inhibit LPS-induced B-cell proliferation. Splenic B cells were 
stimulated with LPS (10 µg/ml) in the presence or absence of memantine, ifenprodil and D-APV in 
concentrations as indicated. Proliferation was determined by 3[H]-Thymidine incorporation (cpm) at 24 
h. Data in the graphs represent the mean + SD relative proliferation of at least three experiments. 
Significant p values were calculated with Student’s t test with *p<0.05, **p<0.01 and ***p<0.001 
(Simma et al., 2014). 
3.2.3 NMDAR antagonists attenuate BCR- as well as LPS-induced B-cell signalling 
Since the antagonists inhibited B-cell proliferation, I addressed how they influence BCR- and 
LPS-induced signalling events. B cells were stimulated with α-IgM (10 µg/ml) or LPS (10 
µg/ml) in the presence or absence of ifenprodil (30 µM) for 1, 5, 10, 30, and 60 min followed 
by Western blot analysis for the expression of pAkt, pS6 and pErk1/2. Compared to untreated 
cells, the presence of ifenprodil led to a reduced activation of these signalling molecules 
(Figure 20, left panel). Interestingly, LPS/TLR4-stimulated B cells showed a very similar 
inhibition of Akt, S6 and Erk1/2 phosphorylation in the presence of ifenprodil (Figure 20, 
right panel). Further experiments investigated the effects of NMDAR antagonists on B-cell 
signalling events at later time points. For this, B cells were activated with α-IgM (10 µg/ml) 
or LPS (10 µg/ml) in the presence or absence of ifenprodil (30 µM) for 12 and 24 h (Figure 
21). 
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Figure 20. NMDAR antagonist ifenprodil attenuates BCR- and LPS-induced signalling events in 
short-term B-cell stimulation. Splenic B cells were activated with α-IgM or LPS (10 µg/ml) in the 
presence or absence of ifenprodil (30 µM) for 1, 5, 10, 30, and 60 min and total protein extracts were 
analysed for the indicated signalling molecules by Western blot. Actin expression served as a loading 
control. Indicated numbers give the relative protein expression after quantification and normalization 
to actin controls. Data are the representative of 3 independent experiments (Simma et al., 2014). 
In cytoplasmic protein extracts of ifenprodil-treated cells, the phosphorylation of S6 and 
Erk1/2 was reduced at 12 and 24 h compared to untreated cells (Figure 21a). In addition, the 
nuclear accumulation of pErk1/2 and NFATc1 was diminished (Figure 21b). Thus, NMDAR 
antagonist ifenprodil downregulates major signalling events of two distinct B-cell activating 
receptors that play an important role in innate and antigen-specific B-cell responses 
(Bhattacharyya et al., 2011; Hock et al., 2013). 
 a)   CE                  b)    NE 
 
 
 
 
 
 
       
 
 
         
Figure 21. Effect of ifenprodil on BCR- and LPS-induced signalling molecules in long-term 
stimulation. Splenic B cells were activated with α-IgM or LPS (10 µg/ml) in the presence or absence of 
ifenprodil (30 µM) for 12 and 24 h and (a) cytoplasmic (CE) and (b) nuclear (NE) protein extracts were 
analysed for the indicated proteins by Western blot. Actin (a) and Lamin B (b) served as protein loading 
controls. Indicated numbers give the relative protein expression after quantification and normalization to 
the controls. Data are the representative of 3 independent experiments (Simma et al., 2014). 
α-IgM LPS
pAkt
actin
pS6
pErk1/2
0   1    5   10  30  60 1    5  10  30  60 min 
none +Ifen.
1 2.4 19 22 23 32 0.5 6.2 11 14 17
1 0.9 2.4 4.4 4.4 4.4 0.8 1.2 2.5 1.7 1.9
1 1.1 1.9 3.5 3.2 4.6 0.1 0.8 1.1 2.2 2.6
0    1   5  10  30  60 1    5  10  30  60
none +Ifen.
1 20 19 21 23 27 7 12 15 17 13
1 2.6 4.5 5.0 5.3 6.3 1.2 2.3 3.1 2.6 2.2
1 25 9.6 7.5 9.2 9.0 7.7 6.8 4.6 3.4 3.9
pErk1/2
actin
1 2.0 21 0.8 5.0 9.0 24 1.0 3.5
α-IgM LPS
pS6
actin
1 116 77 70 95 139 79 91115
0  12 24 12  24 12 24 12  24 h
+- +- Ifen. α-IgM LPS
pErk1/2
NFATc1
Lamin B
1 21 32 16 19 11 12 2 7.6
1 55 110 11 6 47 142 12 5.8
0 12 24  12  24 12  24 12  24 h
+- +- Ifen.
  
  
  Results 
 
 
61 
 
3.2.4 CD40 co-stimulation maintains BCR signalling in the presence of ifenprodil  
Additionally, I investigated the effect of ifenprodil on signalling events in BCR+CD40 co-
stimulated B cells as we had found that CD40 co-stimulation rescues the antagonist-provoked 
inhibition of BCR-induced B-cell proliferation (Simma et al., 2014). B cells were stimulated in 
the absence or presence of ifenprodil (30 µM) for 12 and 24 h. Drug treatment reduced the 
activation of Erk1/2 and S6 in α-IgM+CD40-activated B cells. However, the level of 
phosphorylation of Erk1/2 and S6 was still markedly higher than that found in B cells treated 
with α-IgM plus ifenprodil and similar to the activation found in α-IgM-activated B cells in the 
absence of ifenprodil (Figure 22). These results strongly suggest that the drug-induced 
attenuation of signalling in CD40 co-stimulated B cells still remains above the critical threshold 
needed for B-cell activation. 
 
 
 
 
 
     
       
Figure 22. CD40 co-stimulation maintains strong signalling in the presence of ifenprodil. Splenic B 
cells were activated with α-IgM (10 µg/ml) and CD40 (5 µg/ml) in the presence or absence of ifenprodil 
(30 µM) for 12 and 24 h and cytoplasmic protein extracts were analysed for the indicated signalling 
molecules by Western blot. Actin served as a protein loading control. Indicated numbers give the 
relative protein expression after quantification and normalization to the actin controls. Data are the 
representative of 2 independent experiments (Simma et al., 2014). 
3.2.5 Ifenprodil modulates IL-10 production of B cells 
B10 cells, a small subpopulation of B cells, exert an important immunoregulatory role by 
producing the immunosuppressive cytokine IL-10 (Bhattacharyya et al., 2011; Fillatreau et al., 
2002; Mauri et al., 2003; Yoshizaki et al., 2012). Next, I asked whether the drug-induced 
attenuated B-cell signalling would influence the production of IL-10. B cells were stimulated 
with the mitogens PMA and IO in the presence or absence of ifenprodil for 16 h and IL-10 
mRNA expression was assessed by RT-PCR. IL-10 mRNA was induced upon B-cell 
stimulation. However, additional co-treatment of B cells with ifenprodil resulted in a marked 
repression of IL-10 mRNA compared to untreated B cells (Figure 23a).  
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a)                                                                 b) 
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Figure 23. NMDAR antagonists modulate B cell IL-10 production. a) Splenic B cells were left 
untreated (lane 1) or were activated with PMA/IO in the absence (lane 2) or presence of ifenprodil (10 
and 30 µM, lanes 3 and 4) for 16 h. Cells were re-stimulated with PMA/IO (in the presence of 
monensin) for 6 h before cell harvest. RT-PCR analysis was used to determine IL-10 and actin mRNA 
expression. Data are the representative of 2 experiments. b) B cells were stimulated for 2-3 days with 
either α-IgM+CD40 Abs, CD40 Abs alone or with LPS. Ifenprodil (10 µM) was given at day 1. After 
cell harvest, intracellular expression of IL-10 and IFN-γ was determined by FACS staining and flow 
cytometry. Data are the representative of 2-4 experiments. c, d) B cells from IL-10-GFP tiger mice 
were activated with α-IgM+CD40 Abs or LPS. Ifenprodil (10 or 20 µM) was added after 21-25 h and 
the percentage of cells expressing IL-10-GFP was determined at c) day 2 or d) day 4 with flow 
cytometry. The data in the graphs were caluclated from 2 independent experiments with *p<0.05 and 
**p<0.01 (Simma et al., 2014). 
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In addition, with intracellular IL-10 staining and flow cytomety it was determined how 
ifenprodil affects IL-10 production when added at later time points, i.e. 1 day after B cells had 
been activated with α-IgM+CD40, CD40 Abs alone or LPS (Figure 23b). 
CD40 and LPS are known to give rise to regulatory B10 cells. Consequently, we found that 19-
27% of B cells produced IL-10 after CD40 or LPS stimulation, whereas only 8% of B cells 
were positive for IL-10 after α-IgM+CD40 activation. In LPS- or CD40-treated cultures the 
percentage of IL-10 producers was not substantially altered by ifenprodil, or even reduced. 
However, ifenprodil significantly increased the percentage of IL-10 producers in α-
IgM+CD40-stimulated B cells by 1.5-2.0- fold. There was no effect of ifenprodil on IFN-γ 
production (Figure 23b).  
To confirm above results, B cells from IL-10-GFP knock-in tiger mice were analysed, allowing 
visualization of IL-10 via its GFP (green fluorescent protein)-tag and without intracellular Ab 
staining. Splenic B cells from IL-10-GFP tiger mice were stimulated with α-IgM+CD40 or LPS 
and ifenprodil (10 or 20 µM) was added to the cultures after 21-25 h (Figure 23c, d). A 50% 
increase in the frequeny of IL-10-GFP producing B cells was found at day 2 after α-
IgM+CD40 Ab stimulation (Figure 23c) and a 6-fold increase at day 4 (Figure 23d) when 
ifenprodil was present in the cultures. The frequency of LPS-induced IL-10 producing B cells 
was either reduced or ifenprodil had no major effect on their generation. Thus, ifenprodil can 
foster the generation of B10 cells. 
3.2.6 Ifenprodil impairs IgM and IgG production of LPS-activated B cells 
The major effector function of activated B cells is to produce Abs. Thus, I also assessed the 
impact of NMDAR antagonists on IgM and IgG secretion. B cells were stimulated with LPS 
(10 µg/ml) or LPS plus IL-4. Ifenprodil was added at day 1, 2 or 3 and culture supernatants 
were taken at day 4. The secreted IgM and IgG Abs were determined with ELISA (ELISA was 
performed by our collaborator Dr. F. Lühder, Göttingen). When ifenprodil (10 µM) was added 
at day 1, IgM and IgG production was almost totally abolished, and when added at day 2 
IgM/IgG levels were still significantly decreased (Figure 24). Hence, in addition to B-cell 
proliferation, NMDAR antagonist ifenprodil has a profound inhibitory effect on IgM and IgG 
formation. 
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Figure 24. Ifenprodil blocks IgM/IgG production of LPS-stimulated B cells. Splenic B cells were 
activated with LPS (10 µg/ml) or LPS plus IL-4 (20 ng/ml). Ifenprodil (10 µM) was added at day 1,  2 
or day 3. Harvested culture supernatants, taken at day 4, were analysed for IgM and IgG secretion by 
ELISA. The data in the graphs represent the mean + SD values at OD450 nm, with *p<0.05, **p<0.01 
and ***p<0.001. Data are representative for 2 experiments (Simma et al., 2014). 
In conclusion, NMDAR antagonists attenuate B-cell signalling, proliferation and block Ab 
production, but they can enhance B-cell IL-10 induction. Thus, NMDAR antagonists exert 
potent immunosuppressive and immunoregulatory effects not only on T cells, but also on B 
cells.  
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4. Discussion 
4.1 The puzzle of NMDAR expression in lymphocytes 
The expression of NMDAR subunits in human T cells and their effects on T-cell function, 
like adhesion and proliferation, had been reported in several publications and for murine 
thymocytes a role of NMDARs in Ca2+-mobilization and apoptosis of DP cells was shown 
(Affaticati et al., 2011; Boldyrev, 2005; Levite, 2008; Pacheco et al., 2007). Using RT-PCR 
and intracellular FACS staining, we seemingly also detected the expression of GluN1 and 
GluN2A/B subunits in resting and activated murine CD4+ T cells. However, using two 
different commercial Abs, both detecting extracellular epitopes of the obligatory subunit 
GluN1, a surface expression of GluN1 on thymocytes and peripheral resting or activated T 
cells was not reliably detected using routine FACS staining and flow cytometry (Kahlfuss et 
al., 2014). In addition, in immunoprecipitation assays (data not shown) and Western blot 
analyses the detection of GluN1 protein was not feasible. This became most evident when I 
compared GluN1 expression in thymocytes and brains from GluN1 ko and wildtype mice. 
These analyses led us to conclude that the Abs, used by us and previously by Affaticati et al., 
are unsuitable for the detection of GluN1 in murine lymphocytes. Thus, at the protein level it 
is still unclear whether and to what extent NMDARs are expressed in murine lymphocytes. In 
addition, and as already mentioned by Affaticati et al., we did not detect NMDAR currents in 
T cells in patch clamp experiments (T. Bose, PhD thesis, 2014, (Kahlfuss et al., 2014)). 
Despite the lack of such functional proof, it cannot fully be excluded that NMADRs are 
expressed in lymphocytes at a very low level or only transiently and under specific conditions, 
for instance under cellular stress. NMDAR subunits in murine lymphocytes could exist in 
splice variants and post-translationally modified forms that are not detectable by the used Abs, 
although they detect NMDARs in neuronal cells. In the neuronal synapse the expression of 
NMDARs is low, often less than 10 molecules (Racca et al., 2000), and a single NMDAR 
pumps more Ca2+ than a single Stim-Orai complex of CRAC channels, the major Ca2+ 
channels in lymphocytes (Feske, 2007; Hogan et al., 2010). Thus, a very low expression of 
NMDARs in lymphocytes would make sense. However, I showed that the proliferation of 
thymocytes from GluN1 ko mice was inhibited by ifenprodil to a similar extent as 
proliferation of wt thymocytes. Hence, even if NMDARs are expressed and blocked by the 
antagonists, these should also target additional channels. K+channels expressed on immune 
cells comprise Ca2+-activated (KCa3.1), voltage-activated (Kv1.3) and two pore K2P channels 
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(TASK1, TASK3), which mediate K+-efflux and protect the membrane from depolarization. 
Ca2+-activated KCa3.1 channels and two pore K+channels have been shown to regulate 
immune cell effector function through hyperpolarizing the membrane, which favours Ca2+-
influx through CRAC channels (Cahalan and Chandy, 2009; Meuth et al., 2008). Other ion 
channels like transient receptor potential (TRP) family, voltage-gated Ca2+ (Cav) channels 
and P2X receptor channels also contribute to TCR-induced Ca2+-flux in immune cells (Feske, 
2013).  In our collaborative project, we identified Kv1.3 and KCa3.1 channels as targets of the 
NMDAR antagonists ifenprodil, memantine and MK801 (T. Bose, PhD thesis, 2014, 
(Kahlfuss et al., 2014)). It is conceivable that cross-inhibition of these K+channels results 
from their structural similarities with NMDARs and the resemblance of the Kv1.3 and KCa3.1 
channel pore forming subunits with the binding sites of GluN1/N2A-C subunits of NMDARs. 
The competitive NMDAR antagonist D-APV, which inhibits neuronal NMDARs at 0.7 µM, 
had no effect on T-cell proliferation and showed no effect on the activity of the analysed 
K+channels at concentrations up to 1 mM (Kahlfuss et al., 2014). These results further support 
the notion that NMDARs do not play a major role in murine lymphocytes, at least under the 
applied in vitro conditions.  
4.2 The effects of NMDAR antagonists on T-cell signalling and proliferation 
The NMDAR antagonists memantine and ketamine are used to treat advanced Alzheimer’s 
disease and resistant depression, respectively (Olivares et al., 2012). Thus, besides their 
effects on neuronal activity, it is important to understand how NMDAR antagonists could 
impact on T- and B-cell responses. Using CD3 Ab-induced TCR triggering, I detected 
profound inhibitory effects of NMDAR antagonists on Th cell activation and proliferation. 
Addition of ifenprodil to short-term activated T cells (until 2 h) led to a significant attenuation 
of TCR-induced proximal, activation of the Src tyrosine kinases Lck/Fyn, and downstream 
signalling events including the activation of PLCγ1 and MAPK Erk1/2. In addition, activation 
of the critical Akt-mTOR-S6 signalling axis was also dampened. In long-term-stimulated 
CD4+ T cells ifenprodil treatment reduced the expression of pPLCγ1 and pGSK3β, implying 
an enhanced level of active GSK3β. In line with this and the reduced Ca2+-flux in the 
presence of antagonists (Kahlfuss et al., 2014), the accumulation of nuclear NFATc1 was 
reduced by 65% upon ifenprodil treatment. pmTOR and pS6 levels were also downregulated, 
a further indication for an overall and long-lasting attenuation of TCR signalling in the 
presence of the drug. This reduction in TCR signalling strength correlated with a reduced T-
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cell proliferation upon treatment with either ifenprodil, MK801 or memantine. The extent of 
inhibition depended on the strength of the TCR stimulus, i.e. the CD3 Ab concentration, and 
on the antagonist dose. When Th cells were activated with a weaker TCR stimulus (3 µg/ml 
Ab), the antagonists had a more profound effect and lower drug doses were sufficient to 
induce a significant inhibition of cell proliferation. Furthermore, ifenprodil's inhibitory effect 
on T-cell expansion was compensated by CD28 co-stimulation or exogenous IL-2, reflecting 
a suboptimal TCR-induced signalling and IL-2 production in the presence of the antagonist. 
CD28 signals strengthen TCR signals (Rudd et al., 2009; Weiss, 2009) and, accordingly, I 
found less reduction in pPLCγ1, pmTOR, and pS6 expression by ifenprodil when cells were 
co-stimulated with CD28 Abs. Thus, the extent of inhibitory effects of NMDAR antagonists 
on T-cell activation and proliferation is governed by the strength of the TCR stimulus, 
delivery of CD28 co-stimulation and the drug concentration. One could suppose that 
particularly naive T cells encountering low antigen doses or suboptimal co-stimulation by 
APCs or autoreactive T cells might be most sensitive to NMDAR antagonists.  
In T and B cells Kv1.3 and KCa3.1 channels are involved in compensating the K+-efflux 
needed for efficient Ca2+-influx upon TCR or BCR ligation (Cahalan and Chandy, 2009; 
Conforti, 2012; Lam and Wulff, 2011). Inhibition of Kv1.3 and KCa3.1 channels by specific 
K+ channel blockers inhibit T-cell function and modulate several immunological diseases, 
including rheumatoid arthritis (Toldi et al., 2013), experimental autoimmune encephalitis 
(EAE) (Li et al., 2012), and allergic inflammatory disease (Hua et al., 2013). KCa3.1 channels 
are functionally dominant in naive and early memory T cells, whereas Kv1.3 channels are the 
dominant K+ channels in memory effector T cells. Interestingly, many of our results 
concerning the inhibition of T-cell activation and effector function by NMDAR antagonists 
(Kahlfuss et al., 2014) are resemble those reported for the inhibition of Kv1.3 channels (Hu et 
al., 2007; Hu et al., 2013; Wulff and Zhorov, 2008). This supports our conclusion that 
NMDAR antagonists like ifenprodil or memantine mainly function through the blockade of 
Kv1.3 and KCa3.1 channels. Since NMDAR antagonists cross-inhibit both types of K+ 
channels, they may affect responses of naive as well as memory T cells. NMDAR antagonists 
may also modulate Treg function as Tregs express a similar number of Kv1.3 and KCa3.1 
channels as naive T cells (Reneer et al., 2011; Varga et al., 2009). How NMDAR antagonists 
affect signalling processes in T effector and Treg cells is unknown and should be addressed in 
future studies.  
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Besides those K+ channels, NMDAR antagonists may also impair the function of other 
voltage-gated Ca2+-channels, such as L-type channels or CRAC channels, through side effects 
on the steady state changes in membrane depolarisation. Indeed, MK801 has been shown to 
affect CRAC channel activity (Delaney et al., 2012; Feske, 2013; Omilusik et al., 2011; Shaw 
et al., 2013; Zainullina et al., 2011).  
4.3 NMDAR antagonists in B-cell activation and function 
We considered that, in addition to T cells, application of NMDAR antagonists could also 
cross-target B cells. A summary of the effects of NMDAR antgonists on T cells and B cells is 
given in Table I. We chose to activate B cells by ligation of the BCR through α-IgM Abs as 
well as LPS/TLR4 stimulation. The antagonists ifenprodil, memantine and MK801 impaired 
BCR- and LPS/TLR4-induced B-cell proliferation, but the competitive NMDAR antagonist 
D-APV had no significant influence on B-cell expansion. With respect to the drugs' influence 
on BCR-induced signalling, they attenuated the activation of Erk1/2, Akt, S6, and NFATc1, 
and thus seem to act in B cells via similar mechanisms as in T cells (Kahlfuss et al., 2014; 
Simma et al., 2014). In this context it is interesting that B cells stimulated with BCR plus 
CD40 Abs in the presence of ifenprodil still exhibited higher pErk1/2, pAkt and nuclear 
NFATc1 levels than B cells stimulated with α-IgM alone, although the drug induced a 
reduction in the activation of those molecules. This is consistent with the data from CD3 vs 
CD3+CD28 Ab-activated T cells. Despite attenuated signalling the overall signalling strength 
over time seems to be sufficient to allow proliferation of α-IgM/CD40 co-stimulated B cells 
in the presence of the antagonist.  
Notably, the drugs also downregulated Erk1/2, Akt and NFATc1 activation of LPS/TLR4-
stimulated B cells and blocked their proliferation. This may be of special relevance for innate 
immune responses of B cells, for instance in sepsis. Systemic inflammation induced by LPS 
also seems to affect neuronal pathology, for instance in MS and Parkinson’s disease 
(Cunningham, 2013; Danysz and Parsons, 2012; Martinez-Hernandez et al., 2011; Yanaba et 
al., 2008). Whether non-competitive NMDAR antagonists are suited to milden the course of 
these diseases is an interesting issue for future studies.  
Besides proliferation, NMDAR antagonist ifenprodil inhibited the main function of B cells, 
Ab production. IgM as well as IgG secretion was almost totally aborted when the antagonist 
was added one day after LPS activation of B cells and it was still significantly reduced when 
ifenprodil was added at day 2. So far, we can only speculate that subtle changes in signalling 
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contribute to this effect and further experimentation is required to elucidate the exact 
mechanisms. However, it shows the potency of these drugs to also interfere with the 
responses of activated B cells. This may be therapeutically useful to block B cell 
hyperreactivity and autoantibody production in B cell-mediated chronic inflammation. 
 
Although B cells expressed mRNAs of NMDAR subunits, the detection of NMDARs on 
protein level by Western blot analysis was not feasible (data not shown), similar to what we 
found for T cells. As shown by my colleague Dr. T. Bose, the un- and non-competitive 
antagonists, but not D-APV, also blocked Kv1.3 and KCa3.1 channel activity of B cells and 
BCR-induced Ca2+-flux (T. Bose, PhD thesis, 2014, (Kahlfuss et al., 2014)). Thus, the drugs 
act through cross-inhibition of those K+ channels rather than specific inhibition of NMDARs 
Table 1. Summary of the 
effects of NMDAR antagonists 
on T- and B-cell signalling and 
function. Arrows indicate            
     attenuation        enhancement,        
      no or little attenuation; green 
colour indicates data are 
provided by Dr. T. Bose (PhD 
thesis 2014; (Kahlfuss et al., 
2014; Simma et al., 2014)).  
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expressed on B cells, similar to the data from T cells. A reduced proliferation and class switch 
of memory B cells was found for specific K+ channel inhibitors (Matsumoto et al., 2011; 
Wulff et al., 2004). This supports our finding that the used un- and non-competitive NMDAR 
antagonists act on B cells via cross-inhibition of Kv1.3 and KCa3.1 channels.  
Regulatory B10 cells control inflammation and immune responses by the temporary 
production of IL-10 (Maseda et al., 2012). B10 cells suppress Th1 differentiation and increase 
the number of CD4+CD25+Foxp3+ regulatory T cells in vivo (Blair et al., 2009). Ifenprodil 
added to B cells 1 day after their activation with BCR/CD40 Abs fostered the generation of 
IL-10 producing B cells, whereas drug treatment at the begin of B cell stimulation (PMA/IO) 
abrogated IL-10 mRNA induction. How ifenprodil modulates B cell signalling in favour of 
IL-10 expression is curently unknown. The induction of IL-10 in B cells is complex and not 
fully understood. It is differentially controlled depending on the activation stimulus and 
availability of IL-21 (Candando et al., 2014). The deletion of ER Ca2+-sensors STIM1 and 
STIM2 in B cells blocks IL-10 production resulting from a reduced Ca2+-level after BCR 
ligation and a reduced induction of NFATp (NFAT1) (Matsumoto et al., 2011). Further 
molecules involved in the regulation of IL-10 induction are CREB (cAMP response element-
binding protein), STAT3 and NFκB, the kinases Btk, CamKII, Erk1/2 and the adaptor protein 
SLP65 (Baba et al., 2014; Balagopalan et al., 2010; Jin et al., 2013). In B cells, the activation 
of Erk1/2 depends on PI-3K activation and Ca2+-mobilization (Iritani et al., 1997; Jacob et al., 
2002). In view that ifenprodil reduces BCR-induced Ca2+-flux and NFATc1 activation and 
attenuates BCR/CD40-induced activation of Erk1/2 and Akt, we assume that addition of 
ifenprodil dampens signalling to a threshold  favourable for IL-10 production.  
Among the NMDAR antagonists used in this thesis only memantine is clinically applied in 
the treatment of Alzheimer's disease as it is well tolerated. In the mouse models of collagen 
induced arthritis and EAE, the mouse model for MS, memantine and MK801, respectively, 
mildened the disease (Bolton and Paul, 1997; Lindblad et al., 2012). Memantine also 
mitigated lung inflammatory responses and acute lung injury induced by bleomycin (Li et al., 
2015). The mechanisms underlying disease amelioration, however, are unclear.  
Here, I show that ifenprodil, MK801 and memantine are potent modulators of T- and B-
lymphocyte proliferation, IgM/IgG secretion and B cell IL-10 production. The NMDAR 
antagonists act on lymphocytes through cross-inhibition of Kv1.3 and KCa3.1 channels and 
interfere with the activation of Akt-mTOR-S6, Erk1/2 and NFATc1 (Kahlfuss et al., 2014; 
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Simma et al., 2014), three critical arms of the T- and B-cell signalling network. The 
possibility of their oral application makes NMDAR antagonists, like memantine, attractive 
immunomodulatory or immunosuppressive drugs to control sytemic inflammation, 
autoimmune diseaes, B- and T-cell neoplasia or transplant rejection. Certainly, further in vivo 
studies in mouse models are needed for such translational approaches. In addition, the side 
effects of NMDAR antagonists on B- and T lymphocytes should be considered when they are 
used in treatments of neuronal disorders. Thus, further exciting findings on NMDAR 
antagonists influencing immune cell responses seem to lie ahead. 
  
  
  References 
 
 
72 
 
5. References 
Ackermann, J.A., D. Radtke, A. Maurberger, T.H. Winkler, and L. Nitschke. 2011. Grb2 
regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2+ 
signalling. The EMBO journal 30:1621-1633. 
Acuto, O., V. Di Bartolo, and F. Michel. 2008. Tailoring T-cell receptor signals by proximal 
negative feedback mechanisms. Nature reviews. Immunology 8:699-712. 
Affaticati, P., O. Mignen, F. Jambou, M.C. Potier, I. Klingel-Schmitt, J. Degrouard, S. 
Peineau, E. Gouadon, G.L. Collingridge, R. Liblau, T. Capiod, and S. Cohen-
Kaminsky. 2011. Sustained calcium signalling and caspase-3 activation involve 
NMDA receptors in thymocytes in contact with dendritic cells. Cell death and 
differentiation 18:99-108. 
Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate 
and acquired immunity. Nature immunology 2:675-680. 
Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell. 2001. Recognition of double-
stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-
738. 
Amigorena, S., D. Choquet, J.L. Teillaud, H. Korn, and W.H. Fridman. 1990. Ion channel 
blockers inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. 
Possible involvement of K+ channels. J Immunol 144:2038-2045. 
Anderson, M., J.M. Suh, E.Y. Kim, and S.E. Dryer. 2011. Functional NMDA receptors with 
atypical properties are expressed in podocytes. American journal of physiology. Cell 
physiology 300:C22-32. 
Aracava, Y., E.F. Pereira, A. Maelicke, and E.X. Albuquerque. 2005. Memantine blocks 
alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate 
receptors in rat hippocampal neurons. The Journal of pharmacology and experimental 
therapeutics 312:1195-1205. 
Baba, Y., and T. Kurosaki. 2011. Impact of Ca2+ signaling on B cell function. Trends in 
immunology 32:589-594. 
Baba, Y., M. Matsumoto, and T. Kurosaki. 2014. Calcium signaling in B cells: regulation of 
cytosolic Ca2+ increase and its sensor molecules, STIM1 and STIM2. Molecular 
immunology 62:339-343. 
Baba, Y., M. Matsumoto, and T. Kurosaki. 2015. Signals controlling the development and 
activity of regulatory B-lineage cells. International immunology  
Balagopalan, L., N.P. Coussens, E. Sherman, L.E. Samelson, and C.L. Sommers. 2010. The 
LAT story: a tale of cooperativity, coordination, and choreography. Cold Spring 
Harbor perspectives in biology 2:a005512. 
Barann, M., H. Bonisch, B.W. Urban, and M. Gothert. 1998. Inhibition of 5-HT3 receptor 
cation channels by ifenprodil in excised patches of N1E-115 cells. Naunyn-
Schmiedeberg's archives of pharmacology 358:145-152. 
Bhattacharyya, S., J. Deb, A.K. Patra, D.A. Thuy Pham, W. Chen, M. Vaeth, F. Berberich-
Siebelt, S. Klein-Hessling, E.D. Lamperti, K. Reifenberg, J. Jellusova, A. Schweizer, 
L. Nitschke, E. Leich, A. Rosenwald, C. Brunner, S. Engelmann, U. Bommhardt, A. 
Avots, M.R. Muller, E. Kondo, and E. Serfling. 2011. NFATc1 affects mouse splenic 
B cell function by controlling the calcineurin--NFAT signaling network. The Journal 
of experimental medicine 208:823-839. 
Bittner, S., and S.G. Meuth. 2013. Targeting ion channels for the treatment of autoimmune 
neuroinflammation. Therapeutic advances in neurological disorders 6:322-336. 
  
  
  References 
 
 
73 
 
Blair, P.A., K.A. Chavez-Rueda, J.G. Evans, M.J. Shlomchik, A. Eddaoudi, D.A. Isenberg, 
M.R. Ehrenstein, and C. Mauri. 2009. Selective targeting of B cells with agonistic 
anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B 
cells and for the suppression of lupus in MRL/lpr mice. J Immunol 182:3492-3502. 
Boldyrev, A.A. 2005. Homocysteinic acid causes oxidative stress in lymphocytes by 
potentiating toxic effect of NMDA. Bulletin of experimental biology and medicine 
140:33-37. 
Boldyrev, A.A., D.O. Carpenter, and P. Johnson. 2005. Emerging evidence for a similar role 
of glutamate receptors in the nervous and immune systems. Journal of neurochemistry 
95:913-918. 
Boldyrev, A.A., V.I. Kazey, T.A. Leinsoo, A.P. Mashkina, O.V. Tyulina, P. Johnson, J.O. 
Tuneva, S. Chittur, and D.O. Carpenter. 2004. Rodent lymphocytes express 
functionally active glutamate receptors. Biochemical and biophysical research 
communications 324:133-139. 
Bolton, C., and C. Paul. 1997. MK-801 limits neurovascular dysfunction during experimental 
allergic encephalomyelitis. The Journal of pharmacology and experimental 
therapeutics 282:397-402. 
Bouaziz, J.D., K. Yanaba, and T.F. Tedder. 2008. Regulatory B cells as inhibitors of immune 
responses and inflammation. Immunological reviews 224:201-214. 
Bozic, M., and J.M. Valdivielso. 2015. The potential of targeting NMDA receptors outside 
the CNS. Expert opinion on therapeutic targets 19:399-413. 
Burkhardt, A.L., M. Brunswick, J.B. Bolen, and J.J. Mond. 1991. Anti-immunoglobulin 
stimulation of B lymphocytes activates src-related protein-tyrosine kinases. 
Proceedings of the National Academy of Sciences of the United States of America 
88:7410-7414. 
Cahalan, M.D., and K.G. Chandy. 2009. The functional network of ion channels in T 
lymphocytes. Immunological reviews 231:59-87. 
Candando, K.M., J.M. Lykken, and T.F. Tedder. 2014. B10 cell regulation of health and 
disease. Immunological reviews 259:259-272. 
Chakraborty, A.K., and A. Weiss. 2014. Insights into the initiation of TCR signaling. Nature 
immunology 15:798-807. 
Chaplin, D.D. 2006. 1. Overview of the human immune response. The Journal of allergy and 
clinical immunology 117:S430-435. 
Chenu, C., C.M. Serre, C. Raynal, B. Burt-Pichat, and P.D. Delmas. 1998. Glutamate 
receptors are expressed by bone cells and are involved in bone resorption. Bone 
22:295-299. 
Chuvpilo, S., E. Jankevics, D. Tyrsin, A. Akimzhanov, D. Moroz, M.K. Jha, J. Schulze-
Luehrmann, B. Santner-Nanan, E. Feoktistova, T. Konig, A. Avots, E. Schmitt, F. 
Berberich-Siebelt, A. Schimpl, and E. Serfling. 2002. Autoregulation of NFATc1/A 
expression facilitates effector T cells to escape from rapid apoptosis. Immunity 
16:881-895. 
Conforti, L. 2012. The ion channel network in T lymphocytes, a target for immunotherapy. 
Clin Immunol 142:105-106. 
Conn, P.J. 2003. Physiological roles and therapeutic potential of metabotropic glutamate 
receptors. Annals of the New York Academy of Sciences 1003:12-21. 
Cross, D.A., D.R. Alessi, P. Cohen, M. Andjelkovich, and B.A. Hemmings. 1995. Inhibition 
of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 
378:785-789. 
  
  
  References 
 
 
74 
 
Cunningham, C. 2013. Microglia and neurodegeneration: the role of systemic inflammation. 
Glia 61:71-90. 
Daggett, A., and X.W. Yang. 2013. Huntington's disease: easing the NMDAR traffic jam. 
Nature medicine 19:971-973. 
Danysz, W., and C.G. Parsons. 2012. Alzheimer's disease, beta-amyloid, glutamate, NMDA 
receptors and memantine--searching for the connections. British journal of 
pharmacology 167:324-352. 
Delaney, A.J., J.M. Power, and P. Sah. 2012. Ifenprodil reduces excitatory synaptic 
transmission by blocking presynaptic P/Q type calcium channels. Journal of 
neurophysiology 107:1571-1575. 
Diehn, M., A.A. Alizadeh, O.J. Rando, C.L. Liu, K. Stankunas, D. Botstein, G.R. Crabtree, 
and P.O. Brown. 2002. Genomic expression programs and the integration of the CD28 
costimulatory signal in T cell activation. In Proceedings of the National Academy of 
Sciences of the United States of America. 11796-11801. 
Engel, I., and C. Murre. 2001. The function of E- and Id proteins in lymphocyte development. 
Nature reviews. Immunology 1:193-199. 
Ferraguti, F., and R. Shigemoto. 2006. Metabotropic glutamate receptors. Cell and tissue 
research 326:483-504. 
Feske, S. 2007. Calcium signalling in lymphocyte activation and disease. Nature reviews. 
Immunology 7:690-702. 
Feske, S. 2013. Ca(2+) influx in T cells: how many ca(2+) channels? Frontiers in 
immunology 4:99. 
Fillatreau, S., C.H. Sweenie, M.J. McGeachy, D. Gray, and S.M. Anderton. 2002. B cells 
regulate autoimmunity by provision of IL-10. Nature immunology 3:944-950. 
Finke, C., U.A. Kopp, M. Scheel, L.M. Pech, C. Soemmer, J. Schlichting, F. Leypoldt, A.U. 
Brandt, J. Wuerfel, C. Probst, C.J. Ploner, H. Pruss, and F. Paul. 2013. Functional and 
structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Annals of 
neurology 74:284-296. 
Fuller, D.M., M. Zhu, C.W. Ou-Yang, S.A. Sullivan, and W. Zhang. 2011. A tale of two 
TRAPs: LAT and LAB in the regulation of lymphocyte development, activation, and 
autoimmunity. Immunologic research 49:97-108. 
Ganor, Y., M. Besser, N. Ben-Zakay, T. Unger, and M. Levite. 2003. Human T cells express a 
functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers 
integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J 
Immunol 170:4362-4372. 
Ganor, Y., and M. Levite. 2014. The neurotransmitter glutamate and human T cells: 
glutamate receptors and glutamate-induced direct and potent effects on normal human 
T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T 
cells. J Neural Transm 121:983-1006. 
Genever, P.G., D.J. Wilkinson, A.J. Patton, N.M. Peet, Y. Hong, A. Mathur, J.D. Erusalimsky, 
and T.M. Skerry. 1999. Expression of a functional N-methyl-D-aspartate-type 
glutamate receptor by bone marrow megakaryocytes. Blood 93:2876-2883. 
Germain, R.N. 2002. T-cell development and the CD4-CD8 lineage decision. Nature reviews. 
Immunology 2:309-322. 
Groc, L., M. Heine, S.L. Cousins, F.A. Stephenson, B. Lounis, L. Cognet, and D. Choquet. 
2006. NMDA receptor surface mobility depends on NR2A-2B subunits. Proceedings 
of the National Academy of Sciences of the United States of America 103:18769-
18774. 
  
  
  References 
 
 
75 
 
Gwack, Y., S. Feske, S. Srikanth, P.G. Hogan, and A. Rao. 2007. Signalling to transcription: 
store-operated Ca2+ entry and NFAT activation in lymphocytes. Cell calcium 42:145-
156. 
Harnett, M.M. 2004. CD40: a growing cytoplasmic tale. Science's STKE : signal transduction 
knowledge environment 2004:pe25. 
Hayashi, F., K.D. Smith, A. Ozinsky, T.R. Hawn, E.C. Yi, D.R. Goodlett, J.K. Eng, S. Akira, 
D.M. Underhill, and A. Aderem. 2001. The innate immune response to bacterial 
flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103. 
Hock, M., M. Vaeth, R. Rudolf, A.K. Patra, D.A. Pham, K. Muhammad, T. Pusch, T. Bopp, E. 
Schmitt, R. Rost, F. Berberich-Siebelt, D. Tyrsin, S. Chuvpilo, A. Avots, E. Serfling, 
and S. Klein-Hessling. 2013. NFATc1 induction in peripheral T and B lymphocytes. J 
Immunol 190:2345-2353. 
Hogan, P.G., R.S. Lewis, and A. Rao. 2010. Molecular basis of calcium signaling in 
lymphocytes: STIM and ORAI. Annual review of immunology 28:491-533. 
Hogan, P.G., and A. Rao. 2015. Store-operated calcium entry: Mechanisms and modulation. 
Biochemical and biophysical research communications 460:40-49. 
Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. 
Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J 
Immunol 162:3749-3752. 
Hu, L., M. Pennington, Q. Jiang, K.A. Whartenby, and P.A. Calabresi. 2007. Characterization 
of the functional properties of the voltage-gated potassium channel Kv1.3 in human 
CD4+ T lymphocytes. J Immunol 179:4563-4570. 
Hu, L., T. Wang, A.R. Gocke, A. Nath, H. Zhang, J.B. Margolick, K.A. Whartenby, and P.A. 
Calabresi. 2013. Blockade of Kv1.3 potassium channels inhibits differentiation and 
granzyme B secretion of human CD8+ T effector memory lymphocytes. PloS one 
8:e54267. 
Hua, X., T. Deuse, Y.J. Chen, H. Wulff, M. Stubbendorff, R. Kohler, H. Miura, F. Langer, H. 
Reichenspurner, R.C. Robbins, and S. Schrepfer. 2013. The potassium channel 
KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. 
Transplantation 95:285-292. 
Inagaki, N., H. Kuromi, T. Gonoi, Y. Okamoto, H. Ishida, Y. Seino, T. Kaneko, T. Iwanaga, 
and S. Seino. 1995. Expression and role of ionotropic glutamate receptors in 
pancreatic islet cells. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 9:686-691. 
Iravani, M.M., R. Muscat, and Z.L. Kruk. 1999. MK-801 interaction with the 5-HT 
transporter: a real-time study in brain slices using fast cyclic voltammetry. Synapse 
32:212-224. 
Iritani, B.M., K.A. Forbush, M.A. Farrar, and R.M. Perlmutter. 1997. Control of B cell 
development by Ras-mediated activation of Raf. The EMBO journal 16:7019-7031. 
Isakov, N., R.L. Wange, W.H. Burgess, J.D. Watts, R. Aebersold, and L.E. Samelson. 1995. 
ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the 
tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with 
varying affinity. The Journal of experimental medicine 181:375-380. 
Jacob, A., D. Cooney, M. Pradhan, and K.M. Coggeshall. 2002. Convergence of signaling 
pathways on the activation of ERK in B cells. The Journal of biological chemistry 
277:23420-23426. 
Janeway, C.A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annual review of 
immunology 20:197-216. 
  
  
  References 
 
 
76 
 
Jin, G., Y. Hamaguchi, T. Matsushita, M. Hasegawa, D. Le Huu, N. Ishiura, K. Naka, A. 
Hirao, K. Takehara, and M. Fujimoto. 2013. B-cell linker protein expression 
contributes to controlling allergic and autoimmune diseases by mediating IL-10 
production in regulatory B cells. The Journal of allergy and clinical immunology 
131:1674-1682. 
Johnson, J.W., and P. Ascher. 1987. Glycine potentiates the NMDA response in cultured 
mouse brain neurons. Nature 325:529-531. 
Kahlfuss, S. 2015. Der Einfluss von NMDA-Rezeptor-Antagonisten auf durch dendritische 
Zellen induzierte CD4+ T-Zellfunctionen. In PhD thesis, Magdeburg, Germany. 
Kahlfuss, S., N. Simma, J. Mankiewicz, T. Bose, T. Lowinus, S. Klein-Hessling, R. Sprengel, 
B. Schraven, M. Heine, and U. Bommhardt. 2014. Immunosuppression by N-methyl-
D-aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 
channels in T cells. Molecular and cellular biology 34:820-831. 
Kamanaka, M., S.T. Kim, Y.Y. Wan, F.S. Sutterwala, M. Lara-Tejero, J.E. Galan, E. Harhaj, 
and R.A. Flavell. 2006. Expression of interleukin-10 in intestinal lymphocytes 
detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25:941-952. 
Kawai, T., and S. Akira. 2006. TLR signaling. Cell death and differentiation 13:816-825. 
Klein, L., B. Kyewski, P.M. Allen, and K.A. Hogquist. 2014. Positive and negative selection 
of the T cell repertoire: what thymocytes see (and don't see). Nature reviews. 
Immunology 14:377-391. 
Kleopa, K.A. 2011. Autoimmune channelopathies of the nervous system. Current 
neuropharmacology 9:458-467. 
Kliche, S., D. Breitling, M. Togni, R. Pusch, K. Heuer, X. Wang, C. Freund, A. Kasirer-
Friede, G. Menasche, G.A. Koretzky, and B. Schraven. 2006. The ADAP/SKAP55 
signaling module regulates T-cell receptor-mediated integrin activation through 
plasma membrane targeting of Rap1. Molecular and cellular biology 26:7130-7144. 
Kobayashi, T., K. Washiyama, and K. Ikeda. 2006. Inhibition of G protein-activated inwardly 
rectifying K+ channels by ifenprodil. Neuropsychopharmacology : official publication 
of the American College of Neuropsychopharmacology 31:516-524. 
Kraus, M., M.B. Alimzhanov, N. Rajewsky, and K. Rajewsky. 2004. Survival of resting 
mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. 
Cell 117:787-800. 
Kurosaki, T. 1999. Genetic analysis of B cell antigen receptor signaling. Annual review of 
immunology 17:555-592. 
Lam, J., and H. Wulff. 2011. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as 
Targets for Immunosuppression. Drug development research 72:573-584. 
Lee, M.S., and Y.J. Kim. 2007. Signaling pathways downstream of pattern-recognition 
receptors and their cross talk. Annual review of biochemistry 76:447-480. 
Lennon, V.A., T.J. Kryzer, G.E. Griesmann, P.E. O'Suilleabhain, A.J. Windebank, A. 
Woppmann, G.P. Miljanich, and E.H. Lambert. 1995. Calcium-channel antibodies in 
the Lambert-Eaton syndrome and other paraneoplastic syndromes. The New England 
journal of medicine 332:1467-1474. 
Levite, M. 2008. Neurotransmitters activate T-cells and elicit crucial functions via 
neurotransmitter receptors. Current opinion in pharmacology 8:460-471. 
Lewis, R.S., and M.D. Cahalan. 1995. Potassium and calcium channels in lymphocytes. 
Annual review of immunology 13:623-653. 
Li, Y., Y. Liu, X. Peng, W. Liu, F. Zhao, D. Feng, J. Han, Y. Huang, S. Luo, L. Li, S.J. Yue, 
Q. Cheng, X. Huang, and Z. Luo. 2015. NMDA Receptor Antagonist Attenuates 
Bleomycin-Induced Acute Lung Injury. PloS one 10:e0125873. 
  
  
  References 
 
 
77 
 
Li, Z., L. Chen, X. Niu, J. Liu, M. Ping, R. Li, X. Xie, and L. Guo. 2012. Immunomodulatory 
synergy by combining atorvastatin and rapamycin in the treatment of experimental 
autoimmune encephalomyelitis (EAE). Journal of neuroimmunology 250:9-17. 
Lindblad, S.S., P. Mydel, A. Hellvard, I.M. Jonsson, and M.I. Bokarewa. 2012. The N-
methyl-d-aspartic acid receptor antagonist memantine ameliorates and delays the 
development of arthritis by enhancing regulatory T cells. Neuro-Signals 20:61-71. 
Lipton, S.A. 2004. Paradigm shift in NMDA receptor antagonist drug development: 
molecular mechanism of uncompetitive inhibition by memantine in the treatment of 
Alzheimer's disease and other neurologic disorders. Journal of Alzheimer's disease : 
JAD 6:S61-74. 
Liu, S.K., N. Fang, G.A. Koretzky, and C.J. McGlade. 1999. The hematopoietic-specific 
adaptor protein gads functions in T-cell signaling via interactions with the SLP-76 and 
LAT adaptors. Current biology : CB 9:67-75. 
Lombardi, G., C. Dianzani, G. Miglio, P.L. Canonico, and R. Fantozzi. 2001. 
Characterization of ionotropic glutamate receptors in human lymphocytes. British 
journal of pharmacology 133:936-944. 
Love, P.E., and S.M. Hayes. 2010. ITAM-mediated signaling by the T-cell antigen receptor. 
Cold Spring Harbor perspectives in biology 2:a002485. 
Lueg, G., C.C. Gross, H. Lohmann, A. Johnen, A. Kemmling, M. Deppe, J. Groger, J. 
Minnerup, H. Wiendl, S.G. Meuth, and T. Duning. 2015. Clinical relevance of specific 
T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's 
disease. Neurobiology of aging 36:81-89. 
Machado-Vieira, R., G. Salvadore, N. DiazGranados, L. Ibrahim, D. Latov, C. Wheeler-
Castillo, J. Baumann, I.D. Henter, and C.A. Zarate, Jr. 2010. New therapeutic targets 
for mood disorders. TheScientificWorldJournal 10:713-726. 
Malinow, R. 2012. New developments on the role of NMDA receptors in Alzheimer's disease. 
Current opinion in neurobiology 22:559-563. 
Martinez-Hernandez, E., J. Horvath, Y. Shiloh-Malawsky, N. Sangha, M. Martinez-Lage, and 
J. Dalmau. 2011. Analysis of complement and plasma cells in the brain of patients 
with anti-NMDAR encephalitis. Neurology 77:589-593. 
Maseda, D., S.H. Smith, D.J. DiLillo, J.M. Bryant, K.M. Candando, C.T. Weaver, and T.F. 
Tedder. 2012. Regulatory B10 cells differentiate into antibody-secreting cells after 
transient IL-10 production in vivo. J Immunol 188:1036-1048. 
Matsumoto, M., Y. Fujii, A. Baba, M. Hikida, T. Kurosaki, and Y. Baba. 2011. The calcium 
sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 
production. Immunity 34:703-714. 
Matsushita, T., K. Yanaba, J.D. Bouaziz, M. Fujimoto, and T.F. Tedder. 2008. Regulatory B 
cells inhibit EAE initiation in mice while other B cells promote disease progression. 
The Journal of clinical investigation 118:3420-3430. 
Mauri, C., D. Gray, N. Mushtaq, and M. Londei. 2003. Prevention of arthritis by interleukin 
10-producing B cells. The Journal of experimental medicine 197:489-501. 
Mayer, M.L. 2005. Glutamate receptor ion channels. Current opinion in neurobiology 15:282-
288. 
Mayer, M.L., G.L. Westbrook, and P.B. Guthrie. 1984. Voltage-dependent block by Mg2+ of 
NMDA responses in spinal cord neurones. Nature 309:261-263. 
Melchers, F. 2005. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains 
for the B-cell repertoire. Nature reviews. Immunology 5:578-584. 
  
  
  References 
 
 
78 
 
Meuth, S.G., S. Bittner, P. Meuth, O.J. Simon, T. Budde, and H. Wiendl. 2008. TWIK-related 
acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte 
effector functions. The Journal of biological chemistry 283:14559-14570. 
Miglio, G., C. Dianzani, S. Fallarini, R. Fantozzi, and G. Lombardi. 2007. Stimulation of N-
methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to 
fibronectin. Biochemical and biophysical research communications 361:404-409. 
Miglio, G., F. Varsaldi, and G. Lombardi. 2005. Human T lymphocytes express N-methyl-D-
aspartate receptors functionally active in controlling T cell activation. Biochemical 
and biophysical research communications 338:1875-1883. 
Murphy, K., Janeway Jr, CA., Travers, P., Walport, M. 2012. Janeway Immunobiology. 
Garland Science, New York.  
Nakanishi, S. 1992. Molecular diversity of glutamate receptors and implications for brain 
function. Science 258:597-603. 
Nakayama, T., and M. Yamashita. 2010. The TCR-mediated signaling pathways that control 
the direction of helper T cell differentiation. Seminars in immunology 22:303-309. 
Niswender, C.M., and P.J. Conn. 2010. Metabotropic glutamate receptors: physiology, 
pharmacology, and disease. Annual review of pharmacology and toxicology 50:295-
322. 
Okkenhaug, K., M. Turner, and M.R. Gold. 2014. PI3K Signaling in B Cell and T Cell 
Biology. Frontiers in immunology 5:557. 
Olivares, D., V.K. Deshpande, Y. Shi, D.K. Lahiri, N.H. Greig, J.T. Rogers, and X. Huang. 
2012. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment 
for Alzheimer's disease, vascular dementia and Parkinson's disease. Current Alzheimer 
research 9:746-758. 
Omilusik, K., J.J. Priatel, X. Chen, Y.T. Wang, H. Xu, K.B. Choi, R. Gopaul, A. McIntyre-
Smith, H.S. Teh, R. Tan, N.T. Bech-Hansen, D. Waterfield, D. Fedida, S.V. Hunt, and 
W.A. Jefferies. 2011. The Ca(v)1.4 calcium channel is a critical regulator of T cell 
receptor signaling and naive T cell homeostasis. Immunity 35:349-360. 
Orser, B.A., P.S. Pennefather, and J.F. MacDonald. 1997. Multiple mechanisms of ketamine 
blockade of N-methyl-D-aspartate receptors. Anesthesiology 86:903-917. 
Pacheco, R., T. Gallart, C. Lluis, and R. Franco. 2007. Role of glutamate on T-cell mediated 
immunity. Journal of neuroimmunology 185:9-19. 
Pacheco, R., H. Oliva, J.M. Martinez-Navio, N. Climent, F. Ciruela, J.M. Gatell, T. Gallart, J. 
Mallol, C. Lluis, and R. Franco. 2006. Glutamate released by dendritic cells as a novel 
modulator of T cell activation. J Immunol 177:6695-6704. 
Paoletti, P., C. Bellone, and Q. Zhou. 2013. NMDA receptor subunit diversity: impact on 
receptor properties, synaptic plasticity and disease. Nature reviews. Neuroscience 
14:383-400. 
Paoletti, P., and J. Neyton. 2007. NMDA receptor subunits: function and pharmacology. 
Current opinion in pharmacology 7:39-47. 
Partiseti, M., D. Choquet, A. Diu, and H. Korn. 1992. Differential regulation of voltage- and 
calcium-activated potassium channels in human B lymphocytes. J Immunol 148:3361-
3368. 
Patra, A.K., A. Avots, R.P. Zahedi, T. Schuler, A. Sickmann, U. Bommhardt, and E. Serfling. 
2013. An alternative NFAT-activation pathway mediated by IL-7 is critical for early 
thymocyte development. Nature immunology 14:127-135. 
Patra, A.K., T. Drewes, S. Engelmann, S. Chuvpilo, H. Kishi, T. Hunig, E. Serfling, and U.H. 
Bommhardt. 2006. PKB rescues calcineurin/NFAT-induced arrest of Rag expression 
and pre-T cell differentiation. J Immunol 177:4567-4576. 
  
  
  References 
 
 
79 
 
Paz, P.E., S. Wang, H. Clarke, X. Lu, D. Stokoe, and A. Abo. 2001. Mapping the Zap-70 
phosphorylation sites on LAT (linker for activation of T cells) required for recruitment 
and activation of signalling proteins in T cells. The Biochemical journal 356:461-471. 
Pierau, M., S.Y. Na, N. Simma, T. Lowinus, A. Marx, B. Schraven, and U.H. Bommhardt. 
2012. Constitutive Akt1 signals attenuate B-cell receptor signaling and proliferation, 
but enhance B-cell migration and effector function. European journal of immunology 
42:3381-3393. 
Poe, J.C., S.H. Smith, K.M. Haas, K. Yanaba, T. Tsubata, T. Matsushita, and T.F. Tedder. 
2011. Amplified B lymphocyte CD40 signaling drives regulatory B10 cell expansion 
in mice. PloS one 6:e22464. 
Racca, C., F.A. Stephenson, P. Streit, J.D. Roberts, and P. Somogyi. 2000. NMDA receptor 
content of synapses in stratum radiatum of the hippocampal CA1 area. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 20:2512-2522. 
Ramanathan, S., S.S. Mohammad, F. Brilot, and R.C. Dale. 2014. Autoimmune encephalitis: 
recent updates and emerging challenges. Journal of clinical neuroscience : official 
journal of the Neurosurgical Society of Australasia 21:722-730. 
Rammes, G., R. Rupprecht, U. Ferrari, W. Zieglgansberger, and C.G. Parsons. 2001. The N-
methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other 
amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 
and N1E-115 cell systems in a non-competitive manner. Neuroscience letters 306:81-
84. 
Rao, A., C. Luo, and P.G. Hogan. 1997. Transcription factors of the NFAT family: regulation 
and function. Annual review of immunology 15:707-747. 
Rauch, P.J., A. Chudnovskiy, C.S. Robbins, G.F. Weber, M. Etzrodt, I. Hilgendorf, E. Tiglao, 
J.L. Figueiredo, Y. Iwamoto, I. Theurl, R. Gorbatov, M.T. Waring, A.T. Chicoine, M. 
Mouded, M.J. Pittet, M. Nahrendorf, R. Weissleder, and F.K. Swirski. 2012. Innate 
response activator B cells protect against microbial sepsis. Science 335:597-601. 
Reneer, M.C., D.J. Estes, A.C. Velez-Ortega, A. Norris, M. Mayer, and F. Marti. 2011. 
Peripherally induced human regulatory T cells uncouple Kv1.3 activation from TCR-
associated signaling. European journal of immunology 41:3170-3175. 
Robert, V., E. Triffaux, M. Savignac, and L. Pelletier. 2011. Calcium signalling in T-
lymphocytes. Biochimie 93:2087-2094. 
Rogers, S.W., P.I. Andrews, L.C. Gahring, T. Whisenand, K. Cauley, B. Crain, T.E. Hughes, 
S.F. Heinemann, and J.O. McNamara. 1994. Autoantibodies to glutamate receptor 
GluR3 in Rasmussen's encephalitis. Science 265:648-651. 
Rolli, V., M. Gallwitz, T. Wossning, A. Flemming, W.W. Schamel, C. Zurn, and M. Reth. 
2002. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive 
feedback loop. Molecular cell 10:1057-1069. 
Rudd, C.E., A. Taylor, and H. Schneider. 2009. CD28 and CTLA-4 coreceptor expression and 
signal transduction. Immunological reviews 229:12-26. 
Rudolf, R., R. Busch, A.K. Patra, K. Muhammad, A. Avots, J.C. Andrau, S. Klein-Hessling, 
and E. Serfling. 2014. Architecture and expression of the nfatc1 gene in lymphocytes. 
Frontiers in immunology 5:21. 
Salter, M.W., Y. Dong, L.V. Kalia, X.J. Liu, and G. Pitcher. 2009. Regulation of NMDA 
Receptors by Kinases and Phosphatases. In Biology of the NMDA Receptor. A.M. 
Van Dongen, editor Boca Raton (FL).  
Sansing, L.H., E. Tuzun, M.W. Ko, J. Baccon, D.R. Lynch, and J. Dalmau. 2007. A patient 
with encephalitis associated with NMDA receptor antibodies. Nature clinical practice. 
Neurology 3:291-296. 
  
  
  References 
 
 
80 
 
Sarchielli, P., M. Di Filippo, A. Candeliere, D. Chiasserini, A. Mattioni, S. Tenaglia, M. 
Bonucci, and P. Calabresi. 2007. Expression of ionotropic glutamate receptor GLUR3 
and effects of glutamate on MBP- and MOG-specific lymphocyte activation and 
chemotactic migration in multiple sclerosis patients. Journal of neuroimmunology 
188:146-158. 
Schwenk, F., U. Baron, and K. Rajewsky. 1995. A cre-transgenic mouse strain for the 
ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. 
Nucleic acids research 23:5080-5081. 
Seeman, P., C. Caruso, and M. Lasaga. 2008. Dopamine partial agonist actions of the 
glutamate receptor agonists LY 354,740 and LY 379,268. Synapse 62:154-158. 
Serfling, E., F. Berberich-Siebelt, and A. Avots. 2007. NFAT in lymphocytes: a factor for all 
events? Science's STKE : signal transduction knowledge environment 2007:pe42. 
Serfling, E., S. Klein-Hessling, A. Palmetshofer, T. Bopp, M. Stassen, and E. Schmitt. 2006. 
NFAT transcription factors in control of peripheral T cell tolerance. European journal 
of immunology 36:2837-2843. 
Sharma, S., G.M. Findlay, H.S. Bandukwala, S. Oberdoerffer, B. Baust, Z. Li, V. Schmidt, 
P.G. Hogan, D.B. Sacks, and A. Rao. 2011. Dephosphorylation of the nuclear factor of 
activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold 
complex. Proceedings of the National Academy of Sciences of the United States of 
America 108:11381-11386. 
Shaw, P.J., B. Qu, M. Hoth, and S. Feske. 2013. Molecular regulation of CRAC channels and 
their role in lymphocyte function. Cellular and molecular life sciences : CMLS 
70:2637-2656. 
Shleper, M., E. Kartvelishvily, and H. Wolosker. 2005. D-serine is the dominant endogenous 
coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 25:9413-
9417. 
Shohami, E., and A. Biegon. 2014. Novel approach to the role of NMDA receptors in 
traumatic brain injury. CNS & neurological disorders drug targets 13:567-573. 
Simma, N., T. Bose, S. Kahlfuss, J. Mankiewicz, T. Lowinus, F. Luhder, T. Schuler, B. 
Schraven, M. Heine, and U. Bommhardt. 2014. NMDA-receptor antagonists block B-
cell function but foster IL-10 production in BCR/CD40-activated B cells. Cell 
communication and signaling : CCS 12:75. 
Smith-Garvin, J.E., G.A. Koretzky, and M.S. Jordan. 2009. T cell activation. Annual review 
of immunology 27:591-619. 
Sprengel, R., and F.N. Single. 1999. Mice with genetically modified NMDA and AMPA 
receptors. Annals of the New York Academy of Sciences 868:494-501. 
Starr, T.K., S.C. Jameson, and K.A. Hogquist. 2003. Positive and negative selection of T cells. 
Annual review of immunology 21:139-176. 
Swat, W., L. Ignatowicz, H. von Boehmer, and P. Kisielow. 1991. Clonal deletion of 
immature CD4+8+ thymocytes in suspension culture by extrathymic antigen-
presenting cells. Nature 351:150-153. 
Sylvester, M., S. Kliche, S. Lange, S. Geithner, C. Klemm, A. Schlosser, A. Grossmann, U. 
Stelzl, B. Schraven, E. Krause, and C. Freund. 2010. Adhesion and degranulation 
promoting adapter protein (ADAP) is a central hub for phosphotyrosine-mediated 
interactions in T cells. PloS one 5:e11708. 
T. Bose. 2014. Crosstalk between NMDAR Antagonists and Potassium Channels in Murine 
and Human Lymphocytes. In PhD thesis, Magdeburg, Germany. 
  
  
  References 
 
 
81 
 
ten Boekel, E., F. Melchers, and A.G. Rolink. 1998. Precursor B cells showing H chain allelic 
inclusion display allelic exclusion at the level of pre-B cell receptor surface expression. 
Immunity 8:199-207. 
Toldi, G., A. Bajnok, D. Dobi, A. Kaposi, L. Kovacs, B. Vasarhelyi, and A. Balog. 2013. The 
effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human 
peripheral T lymphocytes in rheumatoid arthritis. Immunobiology 218:311-316. 
Tomek, S.E., A.L. Lacrosse, N.E. Nemirovsky, and M.F. Olive. 2013. NMDA Receptor 
Modulators in the Treatment of Drug Addiction. Pharmaceuticals (Basel) 6:251-268. 
van Zelm, M.C., T. Szczepanski, M. van der Burg, and J.J. van Dongen. 2007. Replication 
history of B lymphocytes reveals homeostatic proliferation and extensive antigen-
induced B cell expansion. The Journal of experimental medicine 204:645-655. 
Varga, Z., T. Csepany, F. Papp, A. Fabian, P. Gogolak, A. Toth, and G. Panyi. 2009. 
Potassium channel expression in human CD4+ regulatory and naive T cells from 
healthy subjects and multiple sclerosis patients. Immunology letters 124:95-101. 
Wang, Y., S.R. Brooks, X. Li, A.N. Anzelon, R.C. Rickert, and R.H. Carter. 2002. The 
physiologic role of CD19 cytoplasmic tyrosines. Immunity 17:501-514. 
Weiss, A. 2009. TCR signal transduction: opening the black box. J Immunol 183:4821-4827. 
Wienands, J., and N. Engels. 2001. Multitasking of Ig-alpha and Ig-beta to regulate B cell 
antigen receptor function. International reviews of immunology 20:679-696. 
Wisden, W., and P.H. Seeburg. 1993. Mammalian ionotropic glutamate receptors. Current 
opinion in neurobiology 3:291-298. 
Wulff, H., H.G. Knaus, M. Pennington, and K.G. Chandy. 2004. K+ channel expression 
during B cell differentiation: implications for immunomodulation and autoimmunity. J 
Immunol 173:776-786. 
Wulff, H., and B.S. Zhorov. 2008. K+ channel modulators for the treatment of neurological 
disorders and autoimmune diseases. Chemical reviews 108:1744-1773. 
Yan, Q., T. Barros, P.R. Visperas, S. Deindl, T.A. Kadlecek, A. Weiss, and J. Kuriyan. 2013. 
Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker. 
Molecular and cellular biology 33:2188-2201. 
Yanaba, K., J.D. Bouaziz, T. Matsushita, C.M. Magro, E.W. St Clair, and T.F. Tedder. 2008. 
B-lymphocyte contributions to human autoimmune disease. Immunological reviews 
223:284-299. 
Yanaba, K., J.D. Bouaziz, T. Matsushita, T. Tsubata, and T.F. Tedder. 2009. The 
development and function of regulatory B cells expressing IL-10 (B10 cells) requires 
antigen receptor diversity and TLR signals. J Immunol 182:7459-7472. 
Yoshizaki, A., T. Miyagaki, D.J. DiLillo, T. Matsushita, M. Horikawa, E.I. Kountikov, R. 
Spolski, J.C. Poe, W.J. Leonard, and T.F. Tedder. 2012. Regulatory B cells control T-
cell autoimmunity through IL-21-dependent cognate interactions. Nature 491:264-268. 
Yuan, H., C.M. Low, O.A. Moody, A. Jenkins, and S.F. Traynelis. 2015. Ionotropic GABA 
and Glutamate Receptor Mutations and Human Neurological Diseases. Molecular 
pharmacology  
Zainullina, L.F., R.S. Yamidanov, V.A. Vakhitov, and Y.V. Vakhitova. 2011. NMDA 
receptors as a possible component of store-operated Ca(2)(+) entry in human T-
lymphocytes. Biochemistry. Biokhimiia 76:1220-1226. 
Zhu, J., and W.E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 112:1557-1569. 
 
  
  
  Abbreviations 
 
 
82 
 
6. Abbreviations 
Abs  antibodies 
Akt  Ak thymoma kinase  
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CaM  calmodulin 
CaMK  calmodulin kinase 
CD  cluster of differentiation 
CE  cytoplasmic protein extract 
CLP  common lymphoid progenitor 
CNS  central nervous system 
CRAC  calcium release activated channel 
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DAG  diacylglycerol 
DC  dendritic cell 
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ER  endoplasmic reticulum 
Erk1/2  extracellular signal-regulated kinase 1/2 
FACS  fluorescence activated cell sorting 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
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GluR  glutamate receptor 
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IFN-γ  interferon gamma 
Ig  immunoglobulin 
iGluR  ionotropic glutamate receptor 
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IL  interleukin 
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LPS  lipopolysaccharide 
MAPK  mitogen-activated protein kinases 
MHC  major histocompatibility complex 
mGluR metabotropic glutamate receptor 
mTOR  mammalian target of rapamycin 
MW  molecular weight 
NE  nucelar protein extract 
NFAT   nuclear factor of activated T cells 
NFκB  nuclear factor kappa light chain enhancer of activated B cells 
NMDAR N-methyl-D-aspartate receptor 
PBS  phosphate buffered saline 
PI3-K  phosphoinositide 3-kinase 
PIP2  phosphatidylinositol-4, 5-biphosphate 
PIP3  phosphatidylinositol-3, 4, 5-triphosphate 
PKC  protein kinase C 
PLCγ  phospholipase C gamma 
PMA  phorbol-12-myistate-acetate      
rpm  revolution per minute 
RT  room temperature 
SP  single positive 
Src  sarcoma tyrosine kinase   
STIM1/2 sensor stromal interaction molecule 1/2 
Syk  spleen tyrosine kinase 
TCR  T cell receptor 
tg  transgenic 
Th cell  T helper cell 
TLR4  Toll like receptor 4 
Treg  regulatory T cell 
wt  wildtype 
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